                                                                                                                                                                  IIB




                                                                113TH CONGRESS
                                                                   1ST SESSION                           H. R. 307
                                                                            IN THE SENATE OF THE UNITED STATES
                                                                                 JANUARY 23 (legislative day, JANUARY 3), 2013
                                                                    Received; read twice and referred to the Committee on Health, Education,
                                                                                               Labor, and Pensions




                                                                                                        AN ACT
                                                                To reauthorize certain programs under the Public Health
                                                                   Service Act and the Federal Food, Drug, and Cosmetic
                                                                   Act with respect to public health security and all-hazards
                                                                   preparedness and response, and for other purposes.
                                                                  1               Be it enacted by the Senate and House of Representa-
tkelley on DSK3SPTVN1PROD with                                    2 tives of the United States of America in Congress assembled,
                                                                  1     SECTION 1. SHORT TITLE; TABLE OF CONTENTS.          2
                                                                  2               (a) SHORT TITLE.—This Act may be cited as the
                                                                  3 ‘‘Pandemic and All-Hazards Preparedness Reauthoriza-
                                                                  4 tion Act of 2013’’.
                                                                  5               (b) TABLE            OF       CONTENTS.—The table of contents of
                                                                  6 this Act is as follows:
                                                                        Sec. 1. Short title; table of contents.

                                                                              TITLE I—STRENGTHENING NATIONAL PREPAREDNESS AND
                                                                                   RESPONSE FOR PUBLIC HEALTH EMERGENCIES

                                                                        Sec.    101.     National Health Security Strategy.
                                                                        Sec.    102.     Assistant Secretary for Preparedness and Response.
                                                                        Sec.    103.     National Advisory Committee on Children and Disasters.
                                                                        Sec.    104.     Modernization of the National Disaster Medical System.
                                                                        Sec.    105.     Continuing the role of the Department of Veterans Affairs.

                                                                                TITLE II—OPTIMIZING STATE AND LOCAL ALL-HAZARDS
                                                                                          PREPAREDNESS AND RESPONSE

                                                                        Sec. 201. Temporary redeployment of federally funded personnel during a pub-
                                                                                        lic health emergency.
                                                                        Sec. 202. Improving State and local public health security.
                                                                        Sec. 203. Hospital preparedness and medical surge capacity.
                                                                        Sec. 204. Enhancing situational awareness and biosurveillance.
                                                                        Sec. 205. Eliminating duplicative Project Bioshield reports.

                                                                            TITLE III—ENHANCING MEDICAL COUNTERMEASURE REVIEW

                                                                        Sec.    301.     Special protocol assessment.
                                                                        Sec.    302.     Authorization for medical products for use in emergencies.
                                                                        Sec.    303.     Definitions.
                                                                        Sec.    304.     Enhancing medical countermeasure activities.
                                                                        Sec.    305.     Regulatory management plans.
                                                                        Sec.    306.     Report.
                                                                        Sec.    307.     Pediatric medical countermeasures.

                                                                                 TITLE IV—ACCELERATING MEDICAL COUNTERMEASURE
                                                                                      ADVANCED RESEARCH AND DEVELOPMENT

                                                                        Sec.    401.     BioShield.
                                                                        Sec.    402.     Biomedical Advanced Research and Development Authority.
                                                                        Sec.    403.     Strategic National Stockpile.
tkelley on DSK3SPTVN1PROD with                                          Sec.    404.     National Biodefense Science Board.
                                                                             HR 307 RFS

                                                                  1     TITLE I—STRENGTHENING NA-                        3
                                                                  2        TIONAL PREPAREDNESS AND
                                                                  3        RESPONSE   FOR   PUBLIC
                                                                  4        HEALTH EMERGENCIES
                                                                  5     SEC. 101. NATIONAL HEALTH SECURITY STRATEGY.

                                                                  6               (a) IN GENERAL.—Section 2802 of the Public Health
                                                                  7 Service Act (42 U.S.C. 300hh–1) is amended—
                                                                  8                        (1) in subsection (a)(1), by striking ‘‘2009’’ and
                                                                  9               inserting ‘‘2014’’; and
                                                                10                         (2) in subsection (b)—
                                                                11                                  (A) in paragraph (1)(A), by inserting ‘‘,
                                                                12                         including drills and exercises to ensure medical
                                                                13                         surge capacity for events without notice’’ after
                                                                14                         ‘‘exercises’’; and
                                                                15                                  (B) in paragraph (3)—
                                                                16                                          (i) in the matter preceding subpara-
                                                                17                                  graph (A)—
                                                                18                                                   (I) by striking ‘‘facilities), and
                                                                19                                          trauma care’’ and inserting ‘‘and am-
                                                                20                                          bulatory care facilities and which may
                                                                21                                          include dental health facilities), and
                                                                22                                          trauma care, critical care,’’; and
                                                                23                                                   (II) by inserting ‘‘(including re-
tkelley on DSK3SPTVN1PROD with                                  24                                          lated availability, accessibility, and co-
                                                                             HR 307 RFS

                                                                                                                           4
                                                                  1                                         ordination)’’               after        ‘‘public     health
                                                                  2                                         emergencies’’;
                                                                  3                                         (ii) in subparagraph (A), by inserting
                                                                  4                                 ‘‘and trauma’’ after ‘‘medical’’;
                                                                  5                                         (iii) in subparagraph (B), by striking
                                                                  6                                 ‘‘Medical evacuation and fatality manage-
                                                                  7                                 ment’’ and inserting ‘‘Fatality manage-
                                                                  8                                 ment’’;
                                                                  9                                         (iv) by redesignating subparagraphs
                                                                10                                  (C), (D), and (E) as subparagraphs (D),
                                                                11                                  (E), and (F), respectively;
                                                                12                                          (v) by inserting after subparagraph
                                                                13                                  (B), the following the new subparagraph:
                                                                14                                  ‘‘(C) Coordinated medical triage and evac-
                                                                15                         uation to appropriate medical institutions based
                                                                16                         on patient medical need, taking into account re-
                                                                17                         gionalized systems of care.’’;
                                                                18                                          (vi) in subparagraph (E), as redesig-
                                                                19                                  nated by clause (iv), by inserting ‘‘(which
                                                                20                                  may include such dental health assets)’’
                                                                21                                  after ‘‘medical assets’’; and
                                                                22                                          (vii) by adding at the end the fol-
                                                                23                                  lowing:
tkelley on DSK3SPTVN1PROD with                                  24                                  ‘‘(G) Optimizing a coordinated and flexible
                                                                25                         approach to the medical surge capacity of hos-


                                                                             HR 307 RFS

                                                                                                                           5
                                                                  1                        pitals, other health care facilities, critical care,
                                                                  2                        and trauma care (which may include trauma
                                                                  3                        centers) and emergency medical systems.’’;
                                                                  4                                 (C) in paragraph (4)—
                                                                  5                                         (i) in subparagraph (A), by inserting
                                                                  6                                 ‘‘, including the unique needs and consider-
                                                                  7                                 ations of individuals with disabilities,’’
                                                                  8                                 after ‘‘medical needs of at-risk individ-
                                                                  9                                 uals’’; and
                                                                10                                          (ii) in subparagraph (B), by inserting
                                                                11                                  ‘‘the’’ before ‘‘purpose of this section’’; and
                                                                12                                  (D) by adding at the end the following:
                                                                13                         ‘‘(7) COUNTERMEASURES.—
                                                                14                                  ‘‘(A) Promoting strategic initiatives to ad-
                                                                15                         vance countermeasures to diagnose, mitigate,
                                                                16                         prevent, or treat harm from any biological
                                                                17                         agent or toxin, chemical, radiological, or nuclear
                                                                18                         agent or agents, whether naturally occurring,
                                                                19                         unintentional, or deliberate.
                                                                20                                  ‘‘(B) For purposes of this paragraph, the
                                                                21                         term ‘countermeasures’ has the same meaning
                                                                22                         as the terms ‘qualified countermeasures’ under
                                                                23                         section 319F–1, ‘qualified pandemic and epi-
tkelley on DSK3SPTVN1PROD with                                  24                         demic products’ under section 319F–3, and ‘se-
                                                                25                         curity countermeasures’ under section 319F–2.


                                                                             HR 307 RFS

                                                                  1                        ‘‘(8) MEDICAL               6   AND PUBLIC HEALTH COMMU-
                                                                  2               NITY        RESILIENCY.—Strengthening                               the ability of
                                                                  3               States, local communities, and tribal communities to
                                                                  4               prepare for, respond to, and be resilient in the event
                                                                  5               of public health emergencies, whether naturally oc-
                                                                  6               curring, unintentional, or deliberate by—
                                                                  7                                 ‘‘(A) optimizing alignment and integration
                                                                  8                        of medical and public health preparedness and
                                                                  9                        response planning and capabilities with and into
                                                                10                         routine daily activities; and
                                                                11                                  ‘‘(B) promoting familiarity with local med-
                                                                12                         ical and public health systems.’’.
                                                                13                (b) AT-RISK INDIVIDUALS.—Section 2814 of the
                                                                14 Public Health Service Act (42 U.S.C. 300hh–16) is
                                                                15 amended—
                                                                16                         (1) by striking paragraphs (5), (7), and (8);
                                                                17                         (2)         in         paragraph                 (4),           by     striking
                                                                18                ‘‘2811(b)(3)(B)’’ and inserting ‘‘2802(b)(4)(B)’’;
                                                                19                         (3) by redesignating paragraphs (1) through
                                                                20                (4) as paragraphs (2) through (5), respectively;
                                                                21                         (4) by inserting before paragraph (2) (as so re-
                                                                22                designated), the following:
                                                                23                         ‘‘(1) monitor emerging issues and concerns as
tkelley on DSK3SPTVN1PROD with                                  24                they relate to medical and public health prepared-
                                                                25                ness and response for at-risk individuals in the event


                                                                             HR 307 RFS

                                                                                                                           7
                                                                  1               of a public health emergency declared by the Sec-
                                                                  2               retary under section 319;’’;
                                                                  3                        (5) by amending paragraph (2) (as so redesig-
                                                                  4               nated) to read as follows:
                                                                  5                        ‘‘(2) oversee the implementation of the pre-
                                                                  6               paredness goals described in section 2802(b) with re-
                                                                  7               spect to the public health and medical needs of at-
                                                                  8               risk individuals in the event of a public health emer-
                                                                  9               gency, as described in section 2802(b)(4);’’; and
                                                                10                         (6) by inserting after paragraph (6), the fol-
                                                                11                lowing:
                                                                12                         ‘‘(7) disseminate and, as appropriate, update
                                                                13                novel and best practices of outreach to and care of
                                                                14                at-risk individuals before, during, and following pub-
                                                                15                lic health emergencies in as timely a manner as is
                                                                16                practicable, including from the time a public health
                                                                17                threat is identified; and
                                                                18                         ‘‘(8) ensure that public health and medical in-
                                                                19                formation distributed by the Department of Health
                                                                20                and Human Services during a public health emer-
                                                                21                gency is delivered in a manner that takes into ac-
                                                                22                count the range of communication needs of the in-
tkelley on DSK3SPTVN1PROD with                                  23                tended recipients, including at-risk individuals.’’.
                                                                             HR 307 RFS

                                                                  1     SEC. 102. ASSISTANT SECRETARY FOR PREPAREDNESS AND 8
                                                                  2                             RESPONSE.

                                                                  3               (a) IN GENERAL.—Section 2811 of the Public Health
                                                                  4 Service Act (42 U.S.C. 300hh–10) is amended—
                                                                  5                        (1) in subsection (b)—
                                                                  6                                 (A) in paragraph (3), by inserting ‘‘, secu-
                                                                  7                        rity countermeasures (as defined in section
                                                                  8                        319F–2),’’ after ‘‘qualified countermeasures (as
                                                                  9                        defined in section 319F–1)’’;
                                                                10                                  (B) in paragraph (4), by adding at the end
                                                                11                         the following:
                                                                12                                  ‘‘(D) POLICY                 COORDINATION AND STRA-
                                                                13                         TEGIC DIRECTION.—Provide                                 integrated policy
                                                                14                         coordination and strategic direction with re-
                                                                15                         spect to all matters related to Federal public
                                                                16                         health and medical preparedness and execution
                                                                17                         and deployment of the Federal response for
                                                                18                         public health emergencies and incidents covered
                                                                19                         by the National Response Plan developed pur-
                                                                20                         suant to section 504(6) of the Homeland Secu-
                                                                21                         rity Act of 2002, or any successor plan, before,
                                                                22                         during, and following public health emergencies.
                                                                23                                  ‘‘(E) IDENTIFICATION                            OF       INEFFICIEN-
tkelley on DSK3SPTVN1PROD with                                  24                         CIES.—Identify                  and minimize gaps, duplication,
                                                                25                         and other inefficiencies in medical and public
                                                                26                         health preparedness and response activities and
                                                                             HR 307 RFS

                                                                                                                           9
                                                                  1                        the actions necessary to overcome these obsta-
                                                                  2                        cles.
                                                                  3                                 ‘‘(F) COORDINATION                          OF         GRANTS    AND
                                                                  4                        AGREEMENTS.—Align                           and coordinate medical
                                                                  5                        and public health grants and cooperative agree-
                                                                  6                        ments as applicable to preparedness and re-
                                                                  7                        sponse activities authorized under this Act, to
                                                                  8                        the extent possible, including program require-
                                                                  9                        ments, timelines, and measurable goals, and in
                                                                10                         consultation with the Secretary of Homeland
                                                                11                         Security, to—
                                                                12                                          ‘‘(i) optimize and streamline medical
                                                                13                                  and public health preparedness and re-
                                                                14                                  sponse capabilities and the ability of local
                                                                15                                  communities to respond to public health
                                                                16                                  emergencies; and
                                                                17                                          ‘‘(ii) gather and disseminate best
                                                                18                                  practices among grant and cooperative
                                                                19                                  agreement recipients, as appropriate.
                                                                20                                  ‘‘(G) DRILL                AND         OPERATIONAL              EXER-
                                                                21                         CISES.—Carry                out drills and operational exer-
                                                                22                         cises, in consultation with the Department of
                                                                23                         Homeland Security, the Department of De-
tkelley on DSK3SPTVN1PROD with                                  24                         fense, the Department of Veterans Affairs, and
                                                                25                         other applicable Federal departments and agen-


                                                                             HR 307 RFS

                                                                                                                       10
                                                                  1                        cies, as necessary and appropriate, to identify,
                                                                  2                        inform, and address gaps in and policies related
                                                                  3                        to all-hazards medical and public health pre-
                                                                  4                        paredness and response, including exercises
                                                                  5                        based on—
                                                                  6                                         ‘‘(i) identified threats for which coun-
                                                                  7                                 termeasures are available and for which no
                                                                  8                                 countermeasures are available; and
                                                                  9                                         ‘‘(ii) unknown threats for which no
                                                                10                                  countermeasures are available.
                                                                11                                  ‘‘(H) NATIONAL                 SECURITY PRIORITY.—On
                                                                12                         a periodic basis consult with, as applicable and
                                                                13                         appropriate, the Assistant to the President for
                                                                14                         National Security Affairs, to provide an update
                                                                15                         on, and discuss, medical and public health pre-
                                                                16                         paredness and response activities pursuant to
                                                                17                         this Act and the Federal Food, Drug, and Cos-
                                                                18                         metic Act, including progress on the develop-
                                                                19                         ment, approval, clearance, and licensure of
                                                                20                         medical countermeasures.’’; and
                                                                21                                  (C) by adding at the end the following:
                                                                22                         ‘‘(7) COUNTERMEASURES                            BUDGET PLAN.—De-
                                                                23                velop, and update on an annual basis, a coordinated
tkelley on DSK3SPTVN1PROD with                                  24                5-year budget plan based on the medical counter-
                                                                             HR 307 RFS

                                                                                                                       11
                                                                  1               measure priorities described in subsection (d). Each
                                                                  2               such plan shall—
                                                                  3                                 ‘‘(A) include consideration of the entire
                                                                  4                        medical countermeasures enterprise, includ-
                                                                  5                        ing—
                                                                  6                                         ‘‘(i) basic research and advanced re-
                                                                  7                                 search and development;
                                                                  8                                         ‘‘(ii) approval, clearance, licensure,
                                                                  9                                 and authorized uses of products; and
                                                                10                                          ‘‘(iii) procurement, stockpiling, main-
                                                                11                                  tenance, and replenishment of all products
                                                                12                                  in the Strategic National Stockpile;
                                                                13                                  ‘‘(B) inform prioritization of resources and
                                                                14                         include measurable outputs and outcomes to
                                                                15                         allow for the tracking of the progress made to-
                                                                16                         ward identified priorities;
                                                                17                                  ‘‘(C) identify medical countermeasure life-
                                                                18                         cycle costs to inform planning, budgeting, and
                                                                19                         anticipated needs within the continuum of the
                                                                20                         medical countermeasure enterprise consistent
                                                                21                         with section 319F–2; and
                                                                22                                  ‘‘(D) be made available to the appropriate
                                                                23                         committees of Congress upon request.’’;
tkelley on DSK3SPTVN1PROD with                                  24                         (2) by striking subsection (c) and inserting the
                                                                25                following:


                                                                             HR 307 RFS

                                                                                                                       12
                                                                  1               ‘‘(c) FUNCTIONS.—The Assistant Secretary for Pre-
                                                                  2 paredness and Response shall—
                                                                  3                        ‘‘(1) have lead responsibility within the Depart-
                                                                  4               ment of Health and Human Services for emergency
                                                                  5               preparedness and response policy coordination and
                                                                  6               strategic direction;
                                                                  7                        ‘‘(2) have authority over and responsibility
                                                                  8               for—
                                                                  9                                 ‘‘(A) the National Disaster Medical System
                                                                10                         pursuant to section 2812;
                                                                11                                  ‘‘(B) the Hospital Preparedness Coopera-
                                                                12                         tive Agreement Program pursuant to section
                                                                13                         319C–2;
                                                                14                                  ‘‘(C) the Biomedical Advanced Research
                                                                15                         and Development Authority pursuant to section
                                                                16                         319L;
                                                                17                                  ‘‘(D) the Medical Reserve Corps pursuant
                                                                18                         to section 2813;
                                                                19                                  ‘‘(E) the Emergency System for Advance
                                                                20                         Registration of Volunteer Health Professionals
                                                                21                         pursuant to section 319I; and
                                                                22                                  ‘‘(F) administering grants and related au-
                                                                23                         thorities related to trauma care under parts A
tkelley on DSK3SPTVN1PROD with                                  24                         through C of title XII, such authority to be
                                                                25                         transferred by the Secretary from the Adminis-


                                                                             HR 307 RFS

                                                                                                                       13
                                                                  1                        trator of the Health Resources and Services Ad-
                                                                  2                        ministration to such Assistant Secretary;
                                                                  3                        ‘‘(3) exercise the responsibilities and authorities
                                                                  4               of the Secretary with respect to the coordination
                                                                  5               of—
                                                                  6                                 ‘‘(A) the Public Health Emergency Pre-
                                                                  7                        paredness Cooperative Agreement Program pur-
                                                                  8                        suant to section 319C–1;
                                                                  9                                 ‘‘(B) the Strategic National Stockpile pur-
                                                                10                         suant to section 319F–2; and
                                                                11                                  ‘‘(C) the Cities Readiness Initiative; and
                                                                12                         ‘‘(4) assume other duties as determined appro-
                                                                13                priate by the Secretary.’’; and
                                                                14                         (3) by adding at the end the following:
                                                                15                ‘‘(d) PUBLIC HEALTH EMERGENCY MEDICAL COUN-
                                                                16      TERMEASURES                  ENTERPRISE STRATEGY                            AND      IMPLEMEN-
                                                                17      TATION           PLAN.—
                                                                18                         ‘‘(1) IN        GENERAL.—Not                     later than 180 days
                                                                19                after the date of enactment of this subsection, and
                                                                20                every year thereafter, the Assistant Secretary for
                                                                21                Preparedness and Response shall develop and submit
                                                                22                to the appropriate committees of Congress a coordi-
                                                                23                nated strategy and accompanying implementation
tkelley on DSK3SPTVN1PROD with                                  24                plan for medical countermeasures to address chem-
                                                                25                ical, biological, radiological, and nuclear threats. In


                                                                             HR 307 RFS

                                                                                                                       14
                                                                  1               developing such a plan, the Assistant Secretary for
                                                                  2               Preparedness and Response shall consult with the
                                                                  3               Director of the Biomedical Advanced Research and
                                                                  4               Development Authority, the Director of the National
                                                                  5               Institutes of Health, the Director of the Centers for
                                                                  6               Disease Control and Prevention, and the Commis-
                                                                  7               sioner of Food and Drugs. Such strategy and plan
                                                                  8               shall be known as the ‘Public Health Emergency
                                                                  9               Medical Countermeasures Enterprise Strategy and
                                                                10                Implementation Plan’.
                                                                11                         ‘‘(2) REQUIREMENTS.—The plan under para-
                                                                12                graph (1) shall—
                                                                13                                  ‘‘(A) describe the chemical, biological, radi-
                                                                14                         ological, and nuclear agent or agents that may
                                                                15                         present a threat to the Nation and the cor-
                                                                16                         responding efforts to develop qualified counter-
                                                                17                         measures (as defined in section 319F–1), secu-
                                                                18                         rity countermeasures (as defined in section
                                                                19                         319F–2), or qualified pandemic or epidemic
                                                                20                         products (as defined in section 319F–3) for
                                                                21                         each threat;
                                                                22                                  ‘‘(B) evaluate the progress of all activities
                                                                23                         with respect to such countermeasures or prod-
tkelley on DSK3SPTVN1PROD with                                  24                         ucts, including research, advanced research, de-
                                                                             HR 307 RFS

                                                                                                                       15
                                                                  1                        velopment, procurement, stockpiling, deploy-
                                                                  2                        ment, distribution, and utilization;
                                                                  3                                 ‘‘(C) identify and prioritize near-, mid-,
                                                                  4                        and long-term needs with respect to such coun-
                                                                  5                        termeasures or products to address a chemical,
                                                                  6                        biological, radiological, and nuclear threat or
                                                                  7                        threats;
                                                                  8                                 ‘‘(D) identify, with respect to each cat-
                                                                  9                        egory of threat, a summary of all awards and
                                                                10                         contracts, including advanced research and de-
                                                                11                         velopment and procurement, that includes—
                                                                12                                          ‘‘(i)      the        time        elapsed             from   the
                                                                13                                  issuance of the initial solicitation or re-
                                                                14                                  quest for a proposal to the adjudication
                                                                15                                  (such as the award, denial of award, or so-
                                                                16                                  licitation termination); and
                                                                17                                          ‘‘(ii) an identification of projected
                                                                18                                  timelines, anticipated funding allocations,
                                                                19                                  benchmarks, and milestones for each med-
                                                                20                                  ical countermeasure priority under sub-
                                                                21                                  paragraph (C), including projected needs
                                                                22                                  with regard to replenishment of the Stra-
tkelley on DSK3SPTVN1PROD with                                  23                                  tegic National Stockpile;
                                                                             HR 307 RFS

                                                                                                                       16
                                                                  1                                 ‘‘(E) be informed by the recommendations
                                                                  2                        of the National Biodefense Science Board pur-
                                                                  3                        suant to section 319M;
                                                                  4                                 ‘‘(F) evaluate progress made in meeting
                                                                  5                        timelines, allocations, benchmarks, and mile-
                                                                  6                        stones identified under subparagraph (D)(ii);
                                                                  7                                 ‘‘(G) report on the amount of funds avail-
                                                                  8                        able for procurement in the special reserve fund
                                                                  9                        as defined in section 319F–2(h) and the impact
                                                                10                         this funding will have on meeting the require-
                                                                11                         ments under section 319F–2;
                                                                12                                  ‘‘(H) incorporate input from Federal,
                                                                13                         State, local, and tribal stakeholders;
                                                                14                                  ‘‘(I) identify the progress made in meeting
                                                                15                         the medical countermeasure priorities for at-
                                                                16                         risk individuals (as defined in 2802(b)(4)(B)),
                                                                17                         as applicable under subparagraph (C), including
                                                                18                         with regard to the projected needs for related
                                                                19                         stockpiling and replenishment of the Strategic
                                                                20                         National Stockpile, including by addressing the
                                                                21                         needs of pediatric populations with respect to
                                                                22                         such countermeasures and products in the Stra-
tkelley on DSK3SPTVN1PROD with                                  23                         tegic National Stockpile, including—
                                                                             HR 307 RFS

                                                                                                                       17
                                                                  1                                         ‘‘(i) a list of such countermeasures
                                                                  2                                 and products necessary to address the
                                                                  3                                 needs of pediatric populations;
                                                                  4                                         ‘‘(ii) a description of measures taken
                                                                  5                                 to coordinate with the Office of Pediatric
                                                                  6                                 Therapeutics of the Food and Drug Ad-
                                                                  7                                 ministration to maximize the labeling, dos-
                                                                  8                                 ages, and formulations of such counter-
                                                                  9                                 measures and products for pediatric popu-
                                                                10                                  lations;
                                                                11                                          ‘‘(iii) a description of existing gaps in
                                                                12                                  the Strategic National Stockpile and the
                                                                13                                  development of such countermeasures and
                                                                14                                  products to address the needs of pediatric
                                                                15                                  populations; and
                                                                16                                          ‘‘(iv) an evaluation of the progress
                                                                17                                  made in addressing priorities identified
                                                                18                                  pursuant to subparagraph (C);
                                                                19                                  ‘‘(J) identify the use of authority and ac-
                                                                20                         tivities undertaken pursuant to sections 319F–
                                                                21                         1(b)(1), 319F–1(b)(2), 319F–1(b)(3), 319F–
                                                                22                         1(c),           319F–1(d),                     319F–1(e),              319F–
                                                                23                         2(c)(7)(C)(iii), 319F–2(c)(7)(C)(iv), and 319F–
tkelley on DSK3SPTVN1PROD with                                  24                         2(c)(7)(C)(v) of this Act, and subsections
                                                                25                         (a)(1), (b)(1), and (e) of section 564 of the


                                                                             HR 307 RFS

                                                                                                                       18
                                                                  1                        Federal Food, Drug, and Cosmetic Act, by
                                                                  2                        summarizing—
                                                                  3                                         ‘‘(i) the particular actions that were
                                                                  4                                 taken under the authorities specified, in-
                                                                  5                                 cluding, as applicable, the identification of
                                                                  6                                 the threat agent, emergency, or the bio-
                                                                  7                                 medical countermeasure with respect to
                                                                  8                                 which the authority was used;
                                                                  9                                         ‘‘(ii) the reasons underlying the deci-
                                                                10                                  sion to use such authorities, including, as
                                                                11                                  applicable, the options that were consid-
                                                                12                                  ered and rejected with respect to the use of
                                                                13                                  such authorities;
                                                                14                                          ‘‘(iii) the number of, nature of, and
                                                                15                                  other information concerning the persons
                                                                16                                  and entities that received a grant, coopera-
                                                                17                                  tive agreement, or contract pursuant to the
                                                                18                                  use of such authorities, and the persons
                                                                19                                  and entities that were considered and re-
                                                                20                                  jected for such a grant, cooperative agree-
                                                                21                                  ment, or contract, except that the report
                                                                22                                  need not disclose the identity of any such
                                                                23                                  person or entity;
tkelley on DSK3SPTVN1PROD with                                  24                                          ‘‘(iv) whether, with respect to each
                                                                25                                  procurement that is approved by the Presi-


                                                                             HR 307 RFS

                                                                                                                       19
                                                                  1                                 dent under section 319F–2(c)(6), a con-
                                                                  2                                 tract was entered into within one year
                                                                  3                                 after such approval by the President; and
                                                                  4                                         ‘‘(v) with respect to section 319F–
                                                                  5                                 1(d), for the one-year period for which the
                                                                  6                                 report is submitted, the number of persons
                                                                  7                                 who were paid amounts totaling $100,000
                                                                  8                                 or greater and the number of persons who
                                                                  9                                 were        paid        amounts             totaling          at   least
                                                                10                                  $50,000 but less than $100,000; and
                                                                11                                  ‘‘(K) be made publicly available.
                                                                12                         ‘‘(3) GAO            REPORT.—

                                                                13                                  ‘‘(A) IN       GENERAL.—Not                    later than 1 year
                                                                14                         after the date of the submission to the Congress
                                                                15                         of the first Public Health Emergency Medical
                                                                16                         Countermeasures Enterprise Strategy and Im-
                                                                17                         plementation Plan, the Comptroller General of
                                                                18                         the United States shall conduct an independent
                                                                19                         evaluation, and submit to the appropriate com-
                                                                20                         mittees of Congress a report, concerning such
                                                                21                         Strategy and Implementation Plan.
                                                                22                                  ‘‘(B) CONTENT.—The report described in
                                                                23                         subparagraph (A) shall review and assess—
tkelley on DSK3SPTVN1PROD with                                  24                                          ‘‘(i) the near-term, mid-term, and
                                                                25                                  long-term medical countermeasure needs


                                                                             HR 307 RFS

                                                                                                                       20
                                                                  1                                 and identified priorities of the Federal
                                                                  2                                 Government pursuant to paragraph (2)(C);
                                                                  3                                         ‘‘(ii) the activities of the Department
                                                                  4                                 of Health and Human Services with re-
                                                                  5                                 spect to advanced research and develop-
                                                                  6                                 ment pursuant to section 319L; and
                                                                  7                                         ‘‘(iii) the progress made toward meet-
                                                                  8                                 ing the timelines, allocations, benchmarks,
                                                                  9                                 and milestones identified in the Public
                                                                10                                  Health           Emergency                 Medical            Counter-
                                                                11                                  measures Enterprise Strategy and Imple-
                                                                12                                  mentation Plan under this subsection.
                                                                13                ‘‘(e) PROTECTION                 OF      NATIONAL SECURITY.—In car-
                                                                14 rying out subsections (b)(7) and (d), the Secretary shall
                                                                15 ensure that information and items that could compromise
                                                                16 national security, contain confidential commercial infor-
                                                                17 mation, or contain proprietary information are not dis-
                                                                18 closed.’’.
                                                                19                (b) INTERAGENCY COORDINATION PLAN.—In the
                                                                20 first Public Health Emergency Countermeasures Enter-
                                                                21 prise Strategy and Implementation Plan submitted under
                                                                22 subsection (d) of section 2811 of the Public Health Service
                                                                23 Act (42 U.S.C. 300hh–10) (as added by subsection
tkelley on DSK3SPTVN1PROD with                                  24 (a)(3)), the Secretary of Health and Human Services, in
                                                                25 consultation with the Secretary of Defense, shall include


                                                                             HR 307 RFS

                                                                                                                       21
                                                                  1 a description of the manner in which the Department of
                                                                  2 Health and Human Services is coordinating with the De-
                                                                  3 partment of Defense regarding countermeasure activities
                                                                  4 to address chemical, biological, radiological, and nuclear
                                                                  5 threats. Such report shall include information with respect
                                                                  6 to—
                                                                  7                        (1) the research, advanced research, develop-
                                                                  8               ment, procurement, stockpiling, and distribution of
                                                                  9               countermeasures to meet identified needs; and
                                                                10                         (2) the coordination of efforts between the De-
                                                                11                partment of Health and Human Services and the
                                                                12                Department of Defense to address countermeasure
                                                                13                needs for various segments of the population.
                                                                14      SEC. 103. NATIONAL ADVISORY COMMITTEE ON CHILDREN
                                                                15                              AND DISASTERS.
                                                                16                Subtitle B of title XXVIII of the Public Health Serv-
                                                                17 ice Act (42 U.S.C. 300hh et seq.) is amended by inserting
                                                                18 after section 2811 the following:
                                                                19      ‘‘SEC. 2811A. NATIONAL ADVISORY COMMITTEE ON CHIL-
                                                                20                              DREN AND DISASTERS.
                                                                21                ‘‘(a) ESTABLISHMENT.—The Secretary, in consulta-
                                                                22 tion with the Secretary of Homeland Security, shall estab-
                                                                23 lish an advisory committee to be known as the ‘National
tkelley on DSK3SPTVN1PROD with                                  24 Advisory Committee on Children and Disasters’ (referred
                                                                25 to in this section as the ‘Advisory Committee’).


                                                                             HR 307 RFS

                                                                                                                       22
                                                                  1               ‘‘(b) DUTIES.—The Advisory Committee shall—
                                                                  2                        ‘‘(1) provide advice and consultation with re-
                                                                  3               spect to the activities carried out pursuant to section
                                                                  4               2814, as applicable and appropriate;
                                                                  5                        ‘‘(2) evaluate and provide input with respect to
                                                                  6               the medical and public health needs of children as
                                                                  7               they relate to preparation for, response to, and re-
                                                                  8               covery from all-hazards emergencies; and
                                                                  9                        ‘‘(3) provide advice and consultation with re-
                                                                10                spect to State emergency preparedness and response
                                                                11                activities and children, including related drills and
                                                                12                exercises pursuant to the preparedness goals under
                                                                13                section 2802(b).
                                                                14                ‘‘(c) ADDITIONAL DUTIES.—The Advisory Committee
                                                                15 may provide advice and recommendations to the Secretary
                                                                16 with respect to children and the medical and public health
                                                                17 grants and cooperative agreements as applicable to pre-
                                                                18 paredness and response activities authorized under this
                                                                19 title and title III.
                                                                20                ‘‘(d) MEMBERSHIP.—
                                                                21                         ‘‘(1) IN       GENERAL.—The                    Secretary, in consulta-
                                                                22                tion with such other Secretaries as may be appro-
                                                                23                priate, shall appoint not to exceed 15 members to
tkelley on DSK3SPTVN1PROD with                                  24                the Advisory Committee. In appointing such mem-
                                                                25                bers, the Secretary shall ensure that the total mem-


                                                                             HR 307 RFS

                                                                                                                       23
                                                                  1               bership of the Advisory Committee is an odd num-
                                                                  2               ber.
                                                                  3                        ‘‘(2) REQUIRED                  MEMBERS.—The                    Secretary, in
                                                                  4               consultation with such other Secretaries as may be
                                                                  5               appropriate, may appoint to the Advisory Committee
                                                                  6               under paragraph (1) such individuals as may be ap-
                                                                  7               propriate to perform the duties described in sub-
                                                                  8               sections (b) and (c), which may include—
                                                                  9                                 ‘‘(A) the Assistant Secretary for Prepared-
                                                                10                         ness and Response;
                                                                11                                  ‘‘(B) the Director of the Biomedical Ad-
                                                                12                         vanced Research and Development Authority;
                                                                13                                  ‘‘(C) the Director of the Centers for Dis-
                                                                14                         ease Control and Prevention;
                                                                15                                  ‘‘(D) the Commissioner of Food and
                                                                16                         Drugs;
                                                                17                                  ‘‘(E) the Director of the National Insti-
                                                                18                         tutes of Health;
                                                                19                                  ‘‘(F) the Assistant Secretary of the Admin-
                                                                20                         istration for Children and Families;
                                                                21                                  ‘‘(G) the Administrator of the Federal
                                                                22                         Emergency Management Agency;
                                                                23                                  ‘‘(H) at least two non-Federal health care
tkelley on DSK3SPTVN1PROD with                                  24                         professionals with expertise in pediatric medical
                                                                             HR 307 RFS

                                                                                                                       24
                                                                  1                        disaster planning, preparedness, response, or
                                                                  2                        recovery;
                                                                  3                                 ‘‘(I) at least two representatives from
                                                                  4                        State, local, territorial, or tribal agencies with
                                                                  5                        expertise in pediatric disaster planning, pre-
                                                                  6                        paredness, response, or recovery; and
                                                                  7                                 ‘‘(J) representatives from such Federal
                                                                  8                        agencies (such as the Department of Education
                                                                  9                        and the Department of Homeland Security) as
                                                                10                         determined necessary to fulfill the duties of the
                                                                11                         Advisory Committee, as established under sub-
                                                                12                         sections (b) and (c).
                                                                13                ‘‘(e) MEETINGS.—The Advisory Committee shall
                                                                14 meet not less than biannually.
                                                                15                ‘‘(f) SUNSET.—The Advisory Committee shall termi-
                                                                16 nate on the date that is 5 years after the date of enact-
                                                                17 ment of the Pandemic and All-Hazards Preparedness Re-
                                                                18 authorization Act of 2013.’’.
                                                                19      SEC. 104. MODERNIZATION OF THE NATIONAL DISASTER
                                                                20                              MEDICAL SYSTEM.
                                                                21                Section 2812 of the Public Health Service Act (42
                                                                22 U.S.C. 300hh–11) is amended—
                                                                23                         (1) in subsection (a)(3)—
tkelley on DSK3SPTVN1PROD with                                  24                                  (A) in subparagraph (A), in clause (i) by
                                                                25                         inserting ‘‘, including at-risk individuals as ap-


                                                                             HR 307 RFS

                                                                                                                       25
                                                                  1                        plicable’’ after ‘‘victims of a public health emer-
                                                                  2                        gency’’;
                                                                  3                                 (B) by redesignating subparagraph (C) as
                                                                  4                        subparagraph (E); and
                                                                  5                                 (C) by inserting after subparagraph (B),
                                                                  6                        the following:
                                                                  7                                 ‘‘(C) CONSIDERATIONS                       FOR AT-RISK POPU-
                                                                  8                        LATIONS.—The                    Secretary shall take steps to
                                                                  9                        ensure that an appropriate specialized and fo-
                                                                10                         cused range of public health and medical capa-
                                                                11                         bilities are represented in the National Disaster
                                                                12                         Medical System, which take into account the
                                                                13                         needs of at-risk individuals, in the event of a
                                                                14                         public health emergency.’’.
                                                                15                                  ‘‘(D)        ADMINISTRATION.—The                              Secretary
                                                                16                         may determine and pay claims for reimburse-
                                                                17                         ment for services under subparagraph (A) di-
                                                                18                         rectly or through contracts that provide for
                                                                19                         payment in advance or by way of reimburse-
                                                                20                         ment.’’; and
                                                                21                         (2) in subsection (g), by striking ‘‘such sums as
                                                                22                may be necessary for each of the fiscal years 2007
                                                                23                through 2011’’ and inserting ‘‘$52,700,000 for each
tkelley on DSK3SPTVN1PROD with                                  24                of fiscal years 2013 through 2017’’.
                                                                             HR 307 RFS

                                                                                                                       26
                                                                  1     SEC. 105. CONTINUING THE ROLE OF THE DEPARTMENT OF
                                                                  2                             VETERANS AFFAIRS.
                                                                  3               Section 8117(g) of title 38, United States Code, is
                                                                  4 amended by striking ‘‘such sums as may be necessary to
                                                                  5 carry out this section for each of fiscal years 2007 through
                                                                  6 2011’’ and inserting ‘‘$155,300,000 for each of fiscal
                                                                  7 years 2013 through 2017 to carry out this section’’.
                                                                  8     TITLE II—OPTIMIZING STATE
                                                                  9        AND LOCAL ALL-HAZARDS
                                                                10         PREPAREDNESS   AND RE-
                                                                11         SPONSE
                                                                12      SEC. 201. TEMPORARY REDEPLOYMENT OF FEDERALLY
                                                                13                              FUNDED             PERSONNEL                 DURING               A   PUBLIC
                                                                14                              HEALTH EMERGENCY.
                                                                15                Section 319 of the Public Health Service Act (42
                                                                16 U.S.C. 247d) is amended by adding at the end the fol-
                                                                17 lowing:
                                                                18                ‘‘(e) TEMPORARY REDEPLOYMENT                                       OF     FEDERALLY
                                                                19 FUNDED PERSONNEL DURING                                        A    PUBLIC HEALTH EMER-
                                                                20      GENCY.—

                                                                21                         ‘‘(1) EMERGENCY                    REDEPLOYMENT OF FEDER-
                                                                22                ALLY FUNDED PERSONNEL.—Notwithstanding                                                 any
                                                                23                other provision of law, and subject to paragraph (2),
tkelley on DSK3SPTVN1PROD with                                  24                upon request by the Governor of a State or the chief
                                                                25                of a tribe or such Governor or chief’s designee, the
                                                                26                Secretary may authorize the requesting State or
                                                                             HR 307 RFS

                                                                                                                       27
                                                                  1               tribe to temporarily redeploy, for purposes of imme-
                                                                  2               diately addressing a public health emergency in the
                                                                  3               State or tribe, non-Federal personnel funded in
                                                                  4               whole or in part through, as appropriate, programs
                                                                  5               under this Act.
                                                                  6                        ‘‘(2) ACTIVATION                   OF EMERGENCY REDEPLOY-
                                                                  7               MENT.—
                                                                  8                                 ‘‘(A) PUBLIC              HEALTH EMERGENCY.—The
                                                                  9                        Secretary may authorize a temporary redeploy-
                                                                10                         ment of personnel under paragraph (1) only
                                                                11                         during the period of a public health emergency
                                                                12                         determined pursuant to subsection (a).
                                                                13                                  ‘‘(B) CONTENTS                     OF REQUEST.—To             seek
                                                                14                         authority for a temporary redeployment of per-
                                                                15                         sonnel under paragraph (1), the Governor of a
                                                                16                         State or the chief of a tribe shall submit to the
                                                                17                         Secretary a request for such authority and shall
                                                                18                         include in the request each of the following:
                                                                19                                          ‘‘(i) An assurance that the public
                                                                20                                  health emergency in the geographic area of
                                                                21                                  the requesting State or tribe cannot be
                                                                22                                  adequately and appropriately addressed by
                                                                23                                  the public health workforce otherwise avail-
tkelley on DSK3SPTVN1PROD with                                  24                                  able.
                                                                             HR 307 RFS

                                                                                                                       28
                                                                  1                                         ‘‘(ii) An assurance that the public
                                                                  2                                 health emergency would be addressed more
                                                                  3                                 efficiently and effectively through the re-
                                                                  4                                 quested temporary redeployment of per-
                                                                  5                                 sonnel.
                                                                  6                                         ‘‘(iii) An assurance that the requested
                                                                  7                                 temporary redeployment of personnel is
                                                                  8                                 consistent with any applicable All-Hazards
                                                                  9                                 Public Health Emergency Preparedness
                                                                10                                  and Response Plan under section 319C–1.
                                                                11                                          ‘‘(iv) An identification of—
                                                                12                                                   ‘‘(I) each Federal program from
                                                                13                                          which personnel would be temporarily
                                                                14                                          redeployed pursuant to the requested
                                                                15                                          authority; and
                                                                16                                                   ‘‘(II) the number of personnel
                                                                17                                          who would be so redeployed from each
                                                                18                                          such program.
                                                                19                                          ‘‘(v) Such other information and as-
                                                                20                                  surances as the Secretary may require.
                                                                21                                  ‘‘(C) CONSIDERATION.—In reviewing a re-
                                                                22                         quest for temporary redeployment under para-
                                                                23                         graph (1) of personnel funded through a Fed-
tkelley on DSK3SPTVN1PROD with                                  24                         eral program, the Secretary shall consider the
                                                                             HR 307 RFS

                                                                                                                       29
                                                                  1                        degree to which the program would be adversely
                                                                  2                        affected by the redeployment.
                                                                  3                                 ‘‘(D) TERMINATION                    AND EXTENSION.—

                                                                  4                                         ‘‘(i)          TERMINATION.—A                         State   or
                                                                  5                                 tribe’s authority for a temporary redeploy-
                                                                  6                                 ment of personnel under paragraph (1)
                                                                  7                                 shall terminate upon the earlier of the fol-
                                                                  8                                 lowing:
                                                                  9                                                  ‘‘(I) The Secretary’s determina-
                                                                10                                          tion that the public health emergency
                                                                11                                          no longer exists.
                                                                12                                                   ‘‘(II) Subject to clause (ii), the
                                                                13                                          expiration of the 30-day period fol-
                                                                14                                          lowing the date on which the Sec-
                                                                15                                          retary approved the State or tribe’s
                                                                16                                          request for such authority.
                                                                17                                          ‘‘(ii) EXTENSION                     AUTHORITY.—The
                                                                18                                  Secretary may extend the authority to au-
                                                                19                                  thorize a temporary redeployment of per-
                                                                20                                  sonnel under paragraph (1) beyond the
                                                                21                                  date otherwise applicable under clause
                                                                22                                  (i)(II) if the public health emergency still
                                                                23                                  exists as of such date, but only if—
tkelley on DSK3SPTVN1PROD with                                  24                                                   ‘‘(I) the State or tribe that sub-
                                                                25                                          mitted the initial request for authority


                                                                             HR 307 RFS

                                                                                                                       30
                                                                  1                                         for a temporary redeployment of per-
                                                                  2                                         sonnel submits a request for an exten-
                                                                  3                                         sion of such authority; and
                                                                  4                                                  ‘‘(II) the request for an extension
                                                                  5                                         contains the same type of information
                                                                  6                                         and assurances necessary for the ap-
                                                                  7                                         proval of an initial request for such
                                                                  8                                         authority.
                                                                  9                        ‘‘(3) NOTICE              TO PERSONNEL OF POSSIBILITY
                                                                10                OF REDEPLOYMENT.—The                                  Secretary shall ensure
                                                                11                that, if a State or tribe receives Federal funds for
                                                                12                personnel who are subject to the Secretary’s rede-
                                                                13                ployment authority under this subsection, the State
                                                                14                or tribe gives notice to such personnel of the possi-
                                                                15                bility of redeployment—
                                                                16                                  ‘‘(A) at the time of hiring; or
                                                                17                                  ‘‘(B) in the case of personnel hired before
                                                                18                         the date of the enactment of this subsection, as
                                                                19                         soon as practicable.
                                                                20                         ‘‘(4) NOTICE               TO CONGRESS.—The                            Secretary
                                                                21                shall give notice to the Congress in conjunction with
                                                                22                the approval under this subsection of—
                                                                23                                  ‘‘(A) any initial request for authority for a
tkelley on DSK3SPTVN1PROD with                                  24                         temporary redeployment of personnel; and
                                                                             HR 307 RFS

                                                                                                                       31
                                                                  1                                 ‘‘(B) any request for an extension of such
                                                                  2                        authority.
                                                                  3                        ‘‘(5) GUIDANCE.—The Secretary shall—
                                                                  4                                 ‘‘(A) not later than 6 months after the en-
                                                                  5                        actment of this subsection, issue proposed guid-
                                                                  6                        ance on the temporary redeployment of per-
                                                                  7                        sonnel under this subsection; and
                                                                  8                                 ‘‘(B) after providing notice and a 60-day
                                                                  9                        period for public comment, finalize such guid-
                                                                10                         ance.
                                                                11                         ‘‘(6) REPORT              TO CONGRESS.—Not                       later than 4
                                                                12                years after the date of enactment of the Pandemic
                                                                13                and All-Hazards Preparedness Reauthorization Act
                                                                14                of 2013, the Comptroller General of the United
                                                                15                States shall conduct an independent evaluation, and
                                                                16                submit to the appropriate committees of the Con-
                                                                17                gress a report, on the Secretary’s authority under
                                                                18                this subsection, including—
                                                                19                                  ‘‘(A) a description of how, and under what
                                                                20                         circumstances, such authority has been used by
                                                                21                         States and tribes;
                                                                22                                  ‘‘(B) an analysis of how such authority has
                                                                23                         assisted States and tribes in responding to pub-
tkelley on DSK3SPTVN1PROD with                                  24                         lic health emergencies;
                                                                             HR 307 RFS

                                                                                                                       32
                                                                  1                                 ‘‘(C) an evaluation of how such authority
                                                                  2                        has improved operational efficiencies in re-
                                                                  3                        sponding to public health emergencies;
                                                                  4                                 ‘‘(D) an analysis of the extent to which, if
                                                                  5                        any, Federal programs from which personnel
                                                                  6                        have been temporarily redeployed pursuant to
                                                                  7                        such authority have been adversely affected by
                                                                  8                        the redeployment; and
                                                                  9                                 ‘‘(E) recommendations on how such au-
                                                                10                         thority could be improved to further assist in
                                                                11                         responding to public health emergencies.
                                                                12                         ‘‘(7) DEFINITION.—In this subsection, the term
                                                                13                ‘State’ includes, in addition to the entities listed in
                                                                14                the definition of such term in section 2, the Freely
                                                                15                Associated States.
                                                                16                         ‘‘(8) SUNSET.—The authority under this sub-
                                                                17                section shall terminate on the date that is 5 years
                                                                18                after the date of enactment of the Pandemic and
                                                                19                All-Hazards Preparedness Reauthorization Act of
                                                                20                2013.’’.
                                                                21      SEC. 202. IMPROVING STATE AND LOCAL PUBLIC HEALTH
                                                                22                              SECURITY.
                                                                23                (a) COOPERATIVE AGREEMENTS.—Section 319C–1
tkelley on DSK3SPTVN1PROD with                                  24 of the Public Health Service Act (42 U.S.C. 247d–3a) is
                                                                25 amended—


                                                                             HR 307 RFS

                                                                                                                       33
                                                                  1                        (1) in subsection (b)(1)(C), by striking ‘‘consor-
                                                                  2               tium of entities described in subparagraph (A)’’ and
                                                                  3               inserting ‘‘consortium of States’’;
                                                                  4                        (2) in subsection (b)(2)—
                                                                  5                                 (A) in subparagraph (A)—
                                                                  6                                         (i) by striking clauses (i) and (ii) and
                                                                  7                                 inserting the following:
                                                                  8                                         ‘‘(i) a description of the activities such
                                                                  9                                 entity will carry out under the agreement
                                                                10                                  to meet the goals identified under section
                                                                11                                  2802, including with respect to chemical,
                                                                12                                  biological, radiological, or nuclear threats,
                                                                13                                  whether naturally occurring, unintentional,
                                                                14                                  or deliberate;
                                                                15                                          ‘‘(ii) a description of the activities
                                                                16                                  such entity will carry out with respect to
                                                                17                                  pandemic influenza, as a component of the
                                                                18                                  activities carried out under clause (i), and
                                                                19                                  consistent with the requirements of para-
                                                                20                                  graphs (2) and (5) of subsection (g);’’;
                                                                21                                          (ii) in clause (iv), by striking ‘‘and’’ at
                                                                22                                  the end; and
                                                                23                                          (iii) by adding at the end the fol-
tkelley on DSK3SPTVN1PROD with                                  24                                  lowing:
                                                                             HR 307 RFS

                                                                                                                       34
                                                                  1                                         ‘‘(vi) a description of how, as appro-
                                                                  2                                 priate, the entity may partner with rel-
                                                                  3                                 evant public and private stakeholders in
                                                                  4                                 public health emergency preparedness and
                                                                  5                                 response;
                                                                  6                                         ‘‘(vii) a description of how the entity,
                                                                  7                                 as applicable and appropriate, will coordi-
                                                                  8                                 nate with State emergency preparedness
                                                                  9                                 and response plans in public health emer-
                                                                10                                  gency preparedness, including State edu-
                                                                11                                  cational agencies (as defined in section
                                                                12                                  9101(41) of the Elementary and Sec-
                                                                13                                  ondary Education Act of 1965) and State
                                                                14                                  child care lead agencies (designated under
                                                                15                                  section 658D of the Child Care and Devel-
                                                                16                                  opment Block Grant Act of 1990);
                                                                17                                          ‘‘(viii) in the case of entities that op-
                                                                18                                  erate on the United States-Mexico border
                                                                19                                  or the United States-Canada border, a de-
                                                                20                                  scription of the activities such entity will
                                                                21                                  carry out under the agreement that are
                                                                22                                  specific to the border area including dis-
                                                                23                                  ease detection, identification, investigation,
tkelley on DSK3SPTVN1PROD with                                  24                                  and preparedness and response activities
                                                                25                                  related to emerging diseases and infectious


                                                                             HR 307 RFS

                                                                                                                       35
                                                                  1                                 disease outbreaks whether naturally occur-
                                                                  2                                 ring or due to bioterrorism, consistent with
                                                                  3                                 the requirements of this section; and
                                                                  4                                         ‘‘(ix) a description of any activities
                                                                  5                                 that such entity will use to analyze real-
                                                                  6                                 time clinical specimens for pathogens of
                                                                  7                                 public health or bioterrorism significance,
                                                                  8                                 including any utilization of poison control
                                                                  9                                 centers;’’; and
                                                                10                                  (B) in subparagraph (C), by inserting ‘‘,
                                                                11                         including addressing the needs of at-risk indi-
                                                                12                         viduals,’’ after ‘‘capabilities of such entity’’;
                                                                13                         (3) in subsection (f)—
                                                                14                                  (A) in paragraph (2), by adding ‘‘and’’ at
                                                                15                         the end;
                                                                16                                  (B) in paragraph (3), by striking ‘‘; and’’
                                                                17                         and inserting a period; and
                                                                18                                  (C) by striking paragraph (4);
                                                                19                         (4) in subsection (g)—
                                                                20                                  (A) in paragraph (1), by striking subpara-
                                                                21                         graph (A) and inserting the following:
                                                                22                                  ‘‘(A) include outcome goals representing
                                                                23                         operational achievements of the National Pre-
tkelley on DSK3SPTVN1PROD with                                  24                         paredness             Goals           developed            under       section
                                                                25                         2802(b) with respect to all-hazards, including


                                                                             HR 307 RFS

                                                                                                                       36
                                                                  1                        chemical, biological, radiological, or nuclear
                                                                  2                        threats; and’’; and
                                                                  3                                 (B) in paragraph (2)(A), by adding at the
                                                                  4                        end the following: ‘‘The Secretary shall periodi-
                                                                  5                        cally update, as necessary and appropriate,
                                                                  6                        such pandemic influenza plan criteria and shall
                                                                  7                        require the integration of such criteria into the
                                                                  8                        benchmarks and standards described in para-
                                                                  9                        graph (1).’’;
                                                                10                         (5) by striking subsection (h);
                                                                11                         (6) in subsection (i)—
                                                                12                                  (A) in paragraph (1)—
                                                                13                                          (i) in subparagraph (A)—
                                                                14                                                   (I) by striking ‘‘$824,000,000 for
                                                                15                                          fiscal           year           2007,            of   which
                                                                16                                          $35,000,000 shall be used to carry
                                                                17                                          out subsection (h),’’ and inserting
                                                                18                                          ‘‘$641,900,000 for fiscal year 2013’’;
                                                                19                                          and
                                                                20                                                   (II) by striking ‘‘such sums as
                                                                21                                          may be necessary for each of fiscal
                                                                22                                          years 2008 through 2011’’ and insert-
                                                                23                                          ing ‘‘$641,900,000 for each of fiscal
tkelley on DSK3SPTVN1PROD with                                  24                                          years 2014 through 2017’’;
                                                                25                                          (ii) by striking subparagraph (B);


                                                                             HR 307 RFS

                                                                                                                       37
                                                                  1                                         (iii) by redesignating subparagraphs
                                                                  2                                 (C) and (D) as subparagraphs (B) and
                                                                  3                                 (C), respectively; and
                                                                  4                                         (iv) in subparagraph (C), as so redes-
                                                                  5                                 ignated, by striking ‘‘subparagraph (C)’’
                                                                  6                                 and inserting ‘‘subparagraph (B)’’;
                                                                  7                                 (B) in subparagraphs (C) and (D) of para-
                                                                  8                        graph (3), by striking ‘‘(1)(A)(i)(I)’’ each place
                                                                  9                        it appears and inserting ‘‘(1)(A)’’;
                                                                10                                  (C) in paragraph (4)(B), by striking ‘‘sub-
                                                                11                         section (c)’’ and inserting ‘‘subsection (b)’’; and
                                                                12                                  (D) by adding at the end the following:
                                                                13                         ‘‘(7) AVAILABILITY                     OF COOPERATIVE AGREE-
                                                                14                MENT FUNDS.—
                                                                15                                  ‘‘(A) IN        GENERAL.—Amounts                         provided to
                                                                16                         an eligible entity under a cooperative agreement
                                                                17                         under subsection (a) for a fiscal year and re-
                                                                18                         maining unobligated at the end of such year
                                                                19                         shall remain available to such entity for the
                                                                20                         next fiscal year for the purposes for which such
                                                                21                         funds were provided.
                                                                22                                  ‘‘(B) FUNDS               CONTINGENT ON ACHIEVING
                                                                23                         BENCHMARKS.—The                         continued availability of
tkelley on DSK3SPTVN1PROD with                                  24                         funds under subparagraph (A) with respect to
                                                                25                         an entity shall be contingent upon such entity


                                                                             HR 307 RFS

                                                                                                                       38
                                                                  1                        achieving the benchmarks and submitting the
                                                                  2                        pandemic influenza plan as described in sub-
                                                                  3                        section (g).’’; and
                                                                  4                        (7) in subsection (j), by striking paragraph (3).
                                                                  5               (b) VACCINE TRACKING                           AND       DISTRIBUTION.—Sec-
                                                                  6 tion 319A(e) of the Public Health Service Act (42 U.S.C.
                                                                  7 247d–1(e)) is amended by striking ‘‘such sums for each
                                                                  8 of fiscal years 2007 through 2011’’ and inserting
                                                                  9 ‘‘$30,800,000 for each of fiscal years 2013 through
                                                                10 2017’’.
                                                                11      SEC. 203. HOSPITAL PREPAREDNESS AND MEDICAL SURGE
                                                                12                              CAPACITY.
                                                                13                (a) ALL-HAZARDS PUBLIC HEALTH                                        AND        MEDICAL
                                                                14 RESPONSE                         CURRICULA                  AND            TRAINING.—Section
                                                                15 319F(a)(5)(B) of the Public Health Service Act (42
                                                                16 U.S.C. 247d–6(a)(5)(B)) is amended by striking ‘‘public
                                                                17 health or medical’’ and inserting ‘‘public health, medical,
                                                                18 or dental’’.
                                                                19                (b) ENCOURAGING HEALTH PROFESSIONAL VOLUN-
                                                                20      TEERS.—

                                                                21                         (1) EMERGENCY                    SYSTEM FOR ADVANCE REG-
                                                                22                ISTRATION               OF        VOLUNTEER                  HEALTH             PROFES-
                                                                23                SIONALS.—Section                     319I(k) of the Public Health
tkelley on DSK3SPTVN1PROD with                                  24                Service Act (42 U.S.C. 247d–7b(k)) is amended by
                                                                25                striking ‘‘$2,000,000 for fiscal year 2002, and such


                                                                             HR 307 RFS

                                                                                                                       39
                                                                  1               sums as may be necessary for each of the fiscal
                                                                  2               years             2003        through                 2011’’          and        inserting
                                                                  3               ‘‘$5,000,000 for each of fiscal years 2013 through
                                                                  4               2017’’.
                                                                  5                        (2) VOLUNTEERS.—Section 2813 of the Public
                                                                  6               Health Service Act (42 U.S.C. 300hh–15) is amend-
                                                                  7               ed—
                                                                  8                                 (A) in subsection (d)(2), by adding at the
                                                                  9                        end the following: ‘‘Such training exercises
                                                                10                         shall, as appropriate and applicable, incorporate
                                                                11                         the needs of at-risk individuals in the event of
                                                                12                         a public health emergency.’’; and
                                                                13                                  (B)         in         subsection            (i),       by      striking
                                                                14                         ‘‘$22,000,000 for fiscal year 2007, and such
                                                                15                         sums as may be necessary for each of fiscal
                                                                16                         years 2008 through 2011’’ and inserting
                                                                17                         ‘‘$11,200,000 for each of fiscal years 2013
                                                                18                         through 2017’’.
                                                                19                (c) PARTNERSHIPS                   FOR        STATE        AND      REGIONAL PRE-
                                                                20      PAREDNESS                   TO IMPROVE SURGE CAPACITY.—Section
                                                                21 319C–2 of the Public Health Service Act (42 U.S.C.
                                                                22 247d–3b) is amended—
                                                                23                         (1) in subsection (a), by inserting ‘‘, including
tkelley on DSK3SPTVN1PROD with                                  24                capacity and preparedness to address the needs of
                                                                             HR 307 RFS

                                                                                                                       40
                                                                  1               pediatric and other at-risk populations’’ before the
                                                                  2               period at the end;
                                                                  3                        (2) in subsection (b)(1)(A)(ii), by striking ‘‘cen-
                                                                  4               ters, primary’’ and inserting ‘‘centers, community
                                                                  5               health centers, primary’’;
                                                                  6                        (3) by striking subsection (c) and inserting the
                                                                  7               following:
                                                                  8               ‘‘(c) USE          OF     FUNDS.—An award under subsection
                                                                  9 (a) shall be expended for activities to achieve the prepared-
                                                                10 ness goals described under paragraphs (1), (3), (4), (5),
                                                                11 and (6) of section 2802(b) with respect to all-hazards, in-
                                                                12 cluding chemical, biological, radiological, or nuclear
                                                                13 threats.’’;
                                                                14                         (4) by striking subsection (g) and inserting the
                                                                15                following:
                                                                16                ‘‘(g) COORDINATION.—
                                                                17                         ‘‘(1) LOCAL             RESPONSE CAPABILITIES.—An                      eli-
                                                                18                gible entity shall, to the extent practicable, ensure
                                                                19                that activities carried out under an award under
                                                                20                subsection (a) are coordinated with activities of rel-
                                                                21                evant local Metropolitan Medical Response Systems,
                                                                22                local Medical Reserve Corps, the local Cities Readi-
                                                                23                ness Initiative, and local emergency plans.
tkelley on DSK3SPTVN1PROD with                                  24                         ‘‘(2)       NATIONAL                 COLLABORATION.—Partner-
                                                                25                ships consisting of one or more eligible entities


                                                                             HR 307 RFS

                                                                                                                       41
                                                                  1               under this section may, to the extent practicable,
                                                                  2               collaborate with other partnerships consisting of one
                                                                  3               or more eligible entities under this section for pur-
                                                                  4               poses of national coordination and collaboration with
                                                                  5               respect to activities to achieve the preparedness
                                                                  6               goals described under paragraphs (1), (3), (4), (5),
                                                                  7               and (6) of section 2802(b).’’;
                                                                  8                        (5) in subsection (i)—
                                                                  9                                 (A) by striking ‘‘The requirements of’’ and
                                                                10                         inserting the following:
                                                                11                         ‘‘(1) IN       GENERAL.—The                    requirements of’’; and
                                                                12                                  (B) by adding at the end the following:
                                                                13                         ‘‘(2) MEETING                   GOALS OF NATIONAL HEALTH
                                                                14                SECURITY STRATEGY.—The                                 Secretary shall imple-
                                                                15                ment objective, evidence-based metrics to ensure that
                                                                16                entities receiving awards under this section are
                                                                17                meeting, to the extent practicable, the applicable
                                                                18                goals of the National Health Security Strategy
                                                                19                under section 2802.’’; and
                                                                20                         (6) in subsection (j)—
                                                                21                                  (A) by amending paragraph (1) to read as
                                                                22                         follows:
                                                                23                         ‘‘(1) IN        GENERAL.—For                     purposes of carrying
tkelley on DSK3SPTVN1PROD with                                  24                out this section, there is authorized to be appro-
                                                                             HR 307 RFS

                                                                                                                       42
                                                                  1               priated $374,700,000 for each of fiscal years 2013
                                                                  2               through 2017.’’; and
                                                                  3                                 (B) by adding at the end the following:
                                                                  4                        ‘‘(4) AVAILABILITY                     OF COOPERATIVE AGREE-
                                                                  5               MENT FUNDS.—
                                                                  6                                 ‘‘(A) IN        GENERAL.—Amounts                         provided to
                                                                  7                        an eligible entity under a cooperative agreement
                                                                  8                        under subsection (a) for a fiscal year and re-
                                                                  9                        maining unobligated at the end of such year
                                                                10                         shall remain available to such entity for the
                                                                11                         next fiscal year for the purposes for which such
                                                                12                         funds were provided.
                                                                13                                  ‘‘(B) FUNDS               CONTINGENT ON ACHIEVING
                                                                14                         BENCHMARKS.—The                         continued availability of
                                                                15                         funds under subparagraph (A) with respect to
                                                                16                         an entity shall be contingent upon such entity
                                                                17                         achieving the benchmarks and submitting the
                                                                18                         pandemic influenza plan as required under sub-
                                                                19                         section (i).’’.
                                                                20      SEC. 204. ENHANCING SITUATIONAL AWARENESS AND BIO-
                                                                21                              SURVEILLANCE.
                                                                22                Section 319D of the Public Health Service Act (42
                                                                23 U.S.C. 247d–4) is amended—
tkelley on DSK3SPTVN1PROD with                                  24                         (1) in subsection (b)—
                                                                             HR 307 RFS

                                                                                                                       43
                                                                  1                                 (A) in paragraph (1)(B), by inserting ‘‘poi-
                                                                  2                        son control centers,’’ after ‘‘hospitals,’’;
                                                                  3                                 (B) in paragraph (2), by inserting before
                                                                  4                        the period at the end the following: ‘‘, allowing
                                                                  5                        for coordination to maximize all-hazards med-
                                                                  6                        ical and public health preparedness and re-
                                                                  7                        sponse and to minimize duplication of effort’’;
                                                                  8                        and
                                                                  9                                 (C) in paragraph (3), by inserting before
                                                                10                         the period at the end the following: ‘‘and up-
                                                                11                         date such standards as necessary’’;
                                                                12                         (2) by striking subsection (c); and
                                                                13                         (3) in subsection (d)—
                                                                14                                  (A) in the subsection heading, by striking
                                                                15                         ‘‘PUBLIC HEALTH SITUATIONAL AWARENESS’’
                                                                16                         and inserting ‘‘MODERNIZING PUBLIC HEALTH
                                                                17                         SITUATIONAL AWARENESS                                AND        BIOSURVEIL-
                                                                18                         LANCE’’;

                                                                19                                  (B) in paragraph (1)—
                                                                20                                          (i) by striking ‘‘Pandemic and All-
                                                                21                                  Hazards Preparedness Act’’ and inserting
                                                                22                                  ‘‘Pandemic and All-Hazards Preparedness
                                                                23                                  Reauthorization Act of 2013’’; and
tkelley on DSK3SPTVN1PROD with                                  24                                          (ii) by inserting ‘‘, novel emerging
                                                                25                                  threats,’’ after ‘‘disease outbreaks’’;


                                                                             HR 307 RFS

                                                                                                                       44
                                                                  1                                 (C) by striking paragraph (2) and insert-
                                                                  2                        ing the following:
                                                                  3                        ‘‘(2)         STRATEGY                  AND            IMPLEMENTATION
                                                                  4               PLAN.—Not               later than 180 days after the date of
                                                                  5               enactment of the Pandemic and All-Hazards Pre-
                                                                  6               paredness Reauthorization Act of 2013, the Sec-
                                                                  7               retary shall submit to the appropriate committees of
                                                                  8               Congress a coordinated strategy and an accom-
                                                                  9               panying implementation plan that identifies and
                                                                10                demonstrates the measurable steps the Secretary will
                                                                11                carry out to—
                                                                12                                  ‘‘(A) develop, implement, and evaluate the
                                                                13                         network described in paragraph (1), utilizing
                                                                14                         the elements described in paragraph (3);
                                                                15                                  ‘‘(B) modernize and enhance biosurveil-
                                                                16                         lance activities; and
                                                                17                                  ‘‘(C) improve information sharing, coordi-
                                                                18                         nation, and communication among disparate
                                                                19                         biosurveillance systems supported by the De-
                                                                20                         partment of Health and Human Services.’’;
                                                                21                                  (D) in paragraph (3)(D), by inserting
                                                                22                         ‘‘community health centers, health centers’’
                                                                23                         after ‘‘poison control,’’;
tkelley on DSK3SPTVN1PROD with                                  24                                  (E) in paragraph (5), by striking subpara-
                                                                25                         graph (A) and inserting the following:


                                                                             HR 307 RFS

                                                                                                                       45
                                                                  1                                 ‘‘(A)        utilize        applicable             interoperability
                                                                  2                        standards as determined by the Secretary, and
                                                                  3                        in consultation with the Office of the National
                                                                  4                        Coordinator for Health Information Tech-
                                                                  5                        nology, through a joint public and private sec-
                                                                  6                        tor process;’’; and
                                                                  7                                 (F) by adding at the end the following:
                                                                  8                        ‘‘(6) CONSULTATION                     WITH THE NATIONAL BIO-
                                                                  9               DEFENSE SCIENCE BOARD.—In                                      carrying out this
                                                                10                section and consistent with section 319M, the Na-
                                                                11                tional Biodefense Science Board shall provide expert
                                                                12                advice and guidance, including recommendations, re-
                                                                13                garding the measurable steps the Secretary should
                                                                14                take to modernize and enhance biosurveillance activi-
                                                                15                ties pursuant to the efforts of the Department of
                                                                16                Health and Human Services to ensure comprehen-
                                                                17                sive, real-time, all-hazards biosurveillance capabili-
                                                                18                ties. In complying with the preceding sentence, the
                                                                19                National Biodefense Science Board shall—
                                                                20                                  ‘‘(A) identify the steps necessary to achieve
                                                                21                         a national biosurveillance system for human
                                                                22                         health, with international connectivity, where
                                                                23                         appropriate, that is predicated on State, re-
tkelley on DSK3SPTVN1PROD with                                  24                         gional, and community level capabilities and
                                                                25                         creates a networked system to allow for two-


                                                                             HR 307 RFS

                                                                                                                       46
                                                                  1                        way information flow between and among Fed-
                                                                  2                        eral, State, and local government public health
                                                                  3                        authorities and clinical health care providers;
                                                                  4                                 ‘‘(B) identify any duplicative surveillance
                                                                  5                        programs under the authority of the Secretary,
                                                                  6                        or changes that are necessary to existing pro-
                                                                  7                        grams, in order to enhance and modernize such
                                                                  8                        activities, minimize duplication, strengthen and
                                                                  9                        streamline such activities under the authority of
                                                                10                         the Secretary, and achieve real-time and appro-
                                                                11                         priate data that relate to disease activity, both
                                                                12                         human and zoonotic; and
                                                                13                                  ‘‘(C) coordinate with applicable existing
                                                                14                         advisory committees of the Director of the Cen-
                                                                15                         ters for Disease Control and Prevention, includ-
                                                                16                         ing such advisory committees consisting of rep-
                                                                17                         resentatives from State, local, and tribal public
                                                                18                         health authorities and appropriate public and
                                                                19                         private sector health care entities and academic
                                                                20                         institutions, in order to provide guidance on
                                                                21                         public health surveillance activities.’’;
                                                                22                         (4) in subsection (e)(5), by striking ‘‘4 years
                                                                23                after the date of enactment of the Pandemic and
tkelley on DSK3SPTVN1PROD with                                  24                All-Hazards Preparedness Act’’ and inserting ‘‘3
                                                                25                years after the date of enactment of the Pandemic


                                                                             HR 307 RFS

                                                                                                                       47
                                                                  1               and All-Hazards Preparedness Reauthorization Act
                                                                  2               of 2013’’;
                                                                  3                        (5) in subsection (g), by striking ‘‘such sums as
                                                                  4               may be necessary in each of fiscal years 2007
                                                                  5               through 2011’’ and inserting ‘‘$138,300,000 for
                                                                  6               each of fiscal years 2013 through 2017’’; and
                                                                  7                        (6) by adding at the end the following:
                                                                  8               ‘‘(h) DEFINITION.—For purposes of this section the
                                                                  9 term ‘biosurveillance’ means the process of gathering near
                                                                10 real-time biological data that relates to human and
                                                                11 zoonotic disease activity and threats to human or animal
                                                                12 health, in order to achieve early warning and identification
                                                                13 of such health threats, early detection and prompt ongoing
                                                                14 tracking of health events, and overall situational aware-
                                                                15 ness of disease activity.’’.
                                                                16      SEC. 205. ELIMINATING DUPLICATIVE PROJECT BIOSHIELD
                                                                17                              REPORTS.
                                                                18                Section 5 of the Project Bioshield Act of 2004 (42
                                                                19 U.S.C. 247d–6c) is repealed.
                                                                20      TITLE III—ENHANCING MEDICAL
                                                                21        COUNTERMEASURE REVIEW
                                                                22      SEC. 301. SPECIAL PROTOCOL ASSESSMENT.
                                                                23                Section 505(b)(5)(B) of the Federal Food, Drug, and
tkelley on DSK3SPTVN1PROD with                                  24 Cosmetic Act (21 U.S.C. 355(b)(5)(B)) is amended by
                                                                25 striking ‘‘size of clinical trials intended’’ and all that fol-


                                                                             HR 307 RFS

                                                                                                                       48
                                                                  1 lows through ‘‘. The sponsor or applicant’’ and inserting
                                                                  2 the following: ‘‘size—
                                                                  3                        ‘‘(i)(I) of clinical trials intended to form the
                                                                  4               primary basis of an effectiveness claim; or
                                                                  5                        ‘‘(II) in the case where human efficacy studies
                                                                  6               are not ethical or feasible, of animal and any associ-
                                                                  7               ated clinical trials which, in combination, are in-
                                                                  8               tended to form the primary basis of an effectiveness
                                                                109               claim; or‘‘(ii) with respect to an application for approval
                                                                11                of a biological product under section 351(k) of the
                                                                12                Public Health Service Act, of any necessary clinical
                                                                13                study or studies.
                                                                14 The sponsor or applicant’’.
                                                                15      SEC. 302. AUTHORIZATION FOR MEDICAL PRODUCTS FOR
                                                                16                              USE IN EMERGENCIES.
                                                                17                (a) IN GENERAL.—Section 564 of the Federal Food,
                                                                18 Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) is amend-
                                                                19 ed—
                                                                20                         (1) in subsection (a)—
                                                                21                                  (A) in paragraph (1), by striking ‘‘sections
                                                                22                         505, 510(k), and 515 of this Act’’ and inserting
                                                                23                         ‘‘any provision of this Act’’;
tkelley on DSK3SPTVN1PROD with                                  24                                  (B) in paragraph (2)(A), by striking
                                                                25                         ‘‘under a provision of law referred to in such


                                                                             HR 307 RFS

                                                                                                                       49
                                                                  1                        paragraph’’ and inserting ‘‘under section 505,
                                                                  2                        510(k), or 515 of this Act or section 351 of the
                                                                  3                        Public Health Service Act’’; and
                                                                  4                                 (C) in paragraph (3), by striking ‘‘a provi-
                                                                  5                        sion of law referred to in such paragraph’’ and
                                                                  6                        inserting ‘‘a section of this Act or the Public
                                                                  7                        Health Service Act referred to in paragraph
                                                                  8                        (2)(A)’’;
                                                                  9                        (2) in subsection (b)—
                                                                10                                  (A) in the subsection heading, by striking
                                                                11                         ‘‘EMERGENCY’’ and inserting ‘‘EMERGENCY                                OR
                                                                12                         THREAT JUSTIFYING EMERGENCY AUTHOR-
                                                                13                         IZED      USE’’;
                                                                14                                  (B) in paragraph (1)—
                                                                15                                          (i) in the matter preceding subpara-
                                                                16                                  graph (A), by striking ‘‘may declare an
                                                                17                                  emergency’’ and inserting ‘‘may make a
                                                                18                                  declaration that the circumstances exist’’;
                                                                19                                          (ii) in subparagraph (A), by striking
                                                                20                                  ‘‘specified’’;
                                                                21                                          (iii) in subparagraph (B)—
                                                                22                                                   (I) by striking ‘‘specified’’; and
                                                                23                                                   (II) by striking ‘‘; or’’ and insert-
tkelley on DSK3SPTVN1PROD with                                  24                                          ing a semicolon;
                                                                             HR 307 RFS

                                                                                                                       50
                                                                  1                                         (iv) by amending subparagraph (C) to
                                                                  2                                 read as follows:
                                                                  3                                 ‘‘(C) a determination by the Secretary that
                                                                  4                        there is a public health emergency, or a signifi-
                                                                  5                        cant potential for a public health emergency,
                                                                  6                        that affects, or has a significant potential to af-
                                                                  7                        fect, national security or the health and security
                                                                  8                        of United States citizens living abroad, and that
                                                                  9                        involves a biological, chemical, radiological, or
                                                                10                         nuclear agent or agents, or a disease or condi-
                                                                11                         tion that may be attributable to such agent or
                                                                12                         agents; or’’; and
                                                                13                                          (v) by adding at the end the following:
                                                                14                                  ‘‘(D) the identification of a material threat
                                                                15                         pursuant to section 319F–2 of the Public
                                                                16                         Health Service Act sufficient to affect national
                                                                17                         security or the health and security of United
                                                                18                         States citizens living abroad.’’;
                                                                19                                  (C) in paragraph (2)—
                                                                20                                          (i) in subparagraph (A), by amending
                                                                21                                  clause (ii) to read as follows:
                                                                22                                          ‘‘(ii) a change in the approval status
                                                                23                                  of the product such that the circumstances
tkelley on DSK3SPTVN1PROD with                                  24                                  described in subsection (a)(2) have ceased
                                                                25                                  to exist.’’;


                                                                             HR 307 RFS

                                                                                                                       51
                                                                  1                                         (ii) by striking subparagraph (B); and
                                                                  2                                         (iii) by redesignating subparagraph
                                                                  3                                 (C) as subparagraph (B);
                                                                  4                                 (D) in paragraph (4), by striking ‘‘advance
                                                                  5                        notice of termination, and renewal under this
                                                                  6                        subsection.’’ and inserting ‘‘, and advance no-
                                                                  7                        tice of termination under this subsection.’’; and
                                                                  8                                 (E) by adding at the end the following:
                                                                  9                        ‘‘(5) EXPLANATION                    BY SECRETARY.—If                  an au-
                                                                10                thorization under this section with respect to an un-
                                                                11                approved product or an unapproved use of an ap-
                                                                12                proved product has been in effect for more than 1
                                                                13                year, the Secretary shall provide in writing to the
                                                                14                sponsor of such product an explanation of the sci-
                                                                15                entific, regulatory, or other obstacles to approval, li-
                                                                16                censure, or clearance of such product or use, includ-
                                                                17                ing specific actions to be taken by the Secretary and
                                                                18                the sponsor to overcome such obstacles.’’;
                                                                19                         (3) in subsection (c)—
                                                                20                                  (A) in the matter preceding paragraph
                                                                21                         (1)—
                                                                22                                          (i) by inserting ‘‘the Assistant Sec-
                                                                23                                  retary for Preparedness and Response,’’
tkelley on DSK3SPTVN1PROD with                                  24                                  after ‘‘consultation with’’;
                                                                             HR 307 RFS

                                                                                                                       52
                                                                  1                                         (ii) by striking ‘‘Health and’’ and in-
                                                                  2                                 serting ‘‘Health, and’’; and
                                                                  3                                         (iii) by striking ‘‘circumstances of the
                                                                  4                                 emergency involved’’ and inserting ‘‘appli-
                                                                  5                                 cable circumstances described in subsection
                                                                  6                                 (b)(1)’’;
                                                                  7                                 (B) in paragraph (1), by striking ‘‘speci-
                                                                  8                        fied’’ and inserting ‘‘referred to’’; and
                                                                  9                                 (C) in paragraph (2)(B), by inserting ‘‘,
                                                                10                         taking into consideration the material threat
                                                                11                         posed by the agent or agents identified in a dec-
                                                                12                         laration under subsection (b)(1)(D), if applica-
                                                                13                         ble’’ after ‘‘risks of the product’’;
                                                                14                         (4) in subsection (d)(3), by inserting ‘‘, to the
                                                                15                extent practicable given the circumstances of the
                                                                16                emergency,’’ after ‘‘including’’;
                                                                17                         (5) in subsection (e)—
                                                                18                                  (A) in paragraph (1)(A), by striking ‘‘cir-
                                                                19                         cumstances of the emergency’’ and inserting
                                                                20                         ‘‘applicable circumstances described in sub-
                                                                21                         section (b)(1)’’;
                                                                22                                  (B) in paragraph (1)(B), by amending
                                                                23                         clause (iii) to read as follows:
tkelley on DSK3SPTVN1PROD with                                  24                                          ‘‘(iii) Appropriate conditions with re-
                                                                25                                  spect to collection and analysis of informa-


                                                                             HR 307 RFS

                                                                                                                       53
                                                                  1                                 tion concerning the safety and effectiveness
                                                                  2                                 of the product with respect to the use of
                                                                  3                                 such product during the period when the
                                                                  4                                 authorization is in effect and a reasonable
                                                                  5                                 time following such period.’’;
                                                                  6                                 (C) in paragraph (2)—
                                                                  7                                         (i) in subparagraph (A)—
                                                                  8                                                  (I) by striking ‘‘manufacturer of
                                                                  9                                         the product’’ and inserting ‘‘person’’;
                                                                10                                                   (II) by striking ‘‘circumstances of
                                                                11                                          the emergency’’ and inserting ‘‘appli-
                                                                12                                          cable circumstances described in sub-
                                                                13                                          section (b)(1)’’; and
                                                                14                                                   (III) by inserting at the end be-
                                                                15                                          fore the period ‘‘or in paragraph
                                                                16                                          (1)(B)’’;
                                                                17                                          (ii) in subparagraph (B)(i), by insert-
                                                                18                                  ing before the period at the end ‘‘, except
                                                                19                                  as provided in section 564A with respect to
                                                                20                                  authorized changes to the product expira-
                                                                21                                  tion date’’; and
                                                                22                                          (iii) by amending subparagraph (C) to
                                                                23                                  read as follows:
tkelley on DSK3SPTVN1PROD with                                  24                                  ‘‘(C) In establishing conditions under this
                                                                25                         paragraph with respect to the distribution and


                                                                             HR 307 RFS

                                                                                                                       54
                                                                  1                        administration of the product for the unap-
                                                                  2                        proved use, the Secretary shall not impose con-
                                                                  3                        ditions that would restrict distribution or ad-
                                                                  4                        ministration of the product when distributed or
                                                                  5                        administered for the approved use.’’; and
                                                                  6                                 (D) by amending paragraph (3) to read as
                                                                  7                        follows:
                                                                  8                        ‘‘(3) GOOD             MANUFACTURING PRACTICE; PRE-
                                                                  9               SCRIPTION.—With                    respect to the emergency use of a
                                                                10                product for which an authorization under this sec-
                                                                11                tion is issued (whether an unapproved product or an
                                                                12                unapproved use of an approved product), the Sec-
                                                                13                retary may waive or limit, to the extent appropriate
                                                                14                given the applicable circumstances described in sub-
                                                                15                section (b)(1)—
                                                                16                                  ‘‘(A) requirements regarding current good
                                                                17                         manufacturing practice otherwise applicable to
                                                                18                         the manufacture, processing, packing, or hold-
                                                                19                         ing of products subject to regulation under this
                                                                20                         Act, including such requirements established
                                                                21                         under section 501 or 520(f)(1), and including
                                                                22                         relevant conditions prescribed with respect to
                                                                23                         the       product           by       an        order        under      section
                                                                24                         520(f)(2);
tkelley on DSK3SPTVN1PROD with




                                                                             HR 307 RFS

                                                                                                                       55
                                                                  1                                 ‘‘(B) requirements established under sec-
                                                                  2                        tion 503(b); and
                                                                  3                                 ‘‘(C) requirements established under sec-
                                                                  4                        tion 520(e).’’;
                                                                  5                        (6) in subsection (g)—
                                                                  6                                 (A) in the subsection heading, by inserting
                                                                  7                        ‘‘REVIEW         AND’’          before ‘‘REVOCATION’’;
                                                                  8                                 (B) in paragraph (1), by inserting after
                                                                  9                        the period at the end the following: ‘‘As part of
                                                                10                         such review, the Secretary shall regularly review
                                                                11                         the progress made with respect to the approval,
                                                                12                         licensure, or clearance of—
                                                                13                                  ‘‘(A) an unapproved product for which an
                                                                14                         authorization was issued under this section; or
                                                                15                                  ‘‘(B) an unapproved use of an approved
                                                                16                         product for which an authorization was issued
                                                                17                         under this section.’’; and
                                                                18                                  (C) by amending paragraph (2) to read as
                                                                19                         follows:
                                                                20                         ‘‘(2) REVISION                  AND REVOCATION.—The                    Sec-
                                                                21                retary may revise or revoke an authorization under
                                                                22                this section if—
                                                                23                                  ‘‘(A) the circumstances described under
tkelley on DSK3SPTVN1PROD with                                  24                         subsection (b)(1) no longer exist;
                                                                             HR 307 RFS

                                                                                                                       56
                                                                  1                                 ‘‘(B) the criteria under subsection (c) for
                                                                  2                        issuance of such authorization are no longer
                                                                  3                        met; or
                                                                  4                                 ‘‘(C) other circumstances make such revi-
                                                                  5                        sion or revocation appropriate to protect the
                                                                  6                        public health or safety.’’;
                                                                  7                        (7) in subsection (h)(1), by adding after the pe-
                                                                  8               riod at the end the following: ‘‘The Secretary shall
                                                                  9               make any revisions to an authorization under this
                                                                10                section available on the Internet Web site of the
                                                                11                Food and Drug Administration.’’;
                                                                12                         (8) by adding at the end of subsection (j) the
                                                                13                following:
                                                                14                         ‘‘(4) Nothing in this section shall be construed
                                                                15                as authorizing a delay in the review or other consid-
                                                                16                eration by the Secretary of any application or sub-
                                                                17                mission pending before the Food and Drug Adminis-
                                                                18                tration for a product for which an authorization
                                                                19                under this section is issued.’’; and
                                                                20                         (9) by adding at the end the following:
                                                                21                ‘‘(m) CATEGORIZATION                        OF       LABORATORY TESTS AS-
                                                                22      SOCIATED              WITH DEVICES SUBJECT                                  TO      AUTHORIZA-
                                                                23      TION.—

tkelley on DSK3SPTVN1PROD with                                  24                         ‘‘(1) IN       GENERAL.—In                  issuing an authorization
                                                                25                under this section with respect to a device, the Sec-


                                                                             HR 307 RFS

                                                                                                                       57
                                                                  1               retary may, subject to the provisions of this section,
                                                                  2               determine that a laboratory examination or proce-
                                                                  3               dure associated with such device shall be deemed, for
                                                                  4               purposes of section 353 of the Public Health Service
                                                                  5               Act, to be in a particular category of examinations
                                                                  6               and procedures (including the category described by
                                                                  7               subsection (d)(3) of such section) if, based on the to-
                                                                  8               tality of scientific evidence available to the Sec-
                                                                109               retary—         ‘‘(A) such categorization would be bene-
                                                                11                         ficial to protecting the public health; and
                                                                12                                  ‘‘(B) the known and potential benefits of
                                                                13                         such categorization under the circumstances of
                                                                14                         the authorization outweigh the known and po-
                                                                15                         tential risks of the categorization.
                                                                16                         ‘‘(2) CONDITIONS                     OF DETERMINATION.—The
                                                                17                Secretary may establish appropriate conditions on
                                                                18                the performance of the examination or procedure
                                                                19                pursuant to such determination.
                                                                20                         ‘‘(3) EFFECTIVE                      PERIOD.—A                  determination
                                                                21                under this subsection shall be effective for purposes
                                                                22                of section 353 of the Public Health Service Act not-
                                                                23                withstanding any other provision of that section dur-
tkelley on DSK3SPTVN1PROD with                                  24                ing the effective period of the relevant declaration
                                                                25                under subsection (b).’’.


                                                                             HR 307 RFS

                                                                  1               (b) EMERGENCY USE                    58     OF       MEDICAL PRODUCTS.—
                                                                  2 Subchapter E of chapter V of the Federal Food, Drug,
                                                                  3 and Cosmetic Act (21 U.S.C. 360bbb et seq.) is amended
                                                                  4 by inserting after section 564 the following:
                                                                  5     ‘‘SEC. 564A. EMERGENCY USE OF MEDICAL PRODUCTS.

                                                                  6               ‘‘(a) DEFINITIONS.—In this section:
                                                                  7                        ‘‘(1) ELIGIBLE                  PRODUCT.—The                    term ‘eligible
                                                                  8               product’ means a product that—
                                                                  9                                 ‘‘(A) is approved or cleared under this
                                                                10                         chapter or licensed under section 351 of the
                                                                11                         Public Health Service Act;
                                                                12                                  ‘‘(B)(i) is intended for use to prevent, di-
                                                                13                         agnose, or treat a disease or condition involving
                                                                14                         a biological, chemical, radiological, or nuclear
                                                                15                         agent or agents; or
                                                                16                                  ‘‘(ii) is intended for use to prevent, diag-
                                                                17                         nose, or treat a serious or life-threatening dis-
                                                                18                         ease or condition caused by a product described
                                                                19                         in clause (i); and
                                                                20                                  ‘‘(C) is intended for use during the cir-
                                                                21                         cumstances under which—
                                                                22                                          ‘‘(i) a determination described in sub-
                                                                23                                  paragraph (A), (B), or (C) of section
tkelley on DSK3SPTVN1PROD with                                  24                                  564(b)(1) has been made by the Secretary
                                                                             HR 307 RFS

                                                                                                                       59
                                                                  1                                 of Homeland Security, the Secretary of
                                                                  2                                 Defense, or the Secretary, respectively; or
                                                                  3                                         ‘‘(ii) the identification of a material
                                                                  4                                 threat described in subparagraph (D) of
                                                                  5                                 section 564(b)(1) has been made pursuant
                                                                  6                                 to section 319F–2 of the Public Health
                                                                  7                                 Service Act.
                                                                  8                        ‘‘(2) PRODUCT.—The term ‘product’ means a
                                                                  9               drug, device, or biological product.
                                                                10                ‘‘(b) EXPIRATION DATING.—
                                                                11                         ‘‘(1) IN       GENERAL.—The                     Secretary may extend
                                                                12                the expiration date and authorize the introduction or
                                                                13                delivery for introduction into interstate commerce of
                                                                14                an eligible product after the expiration date provided
                                                                15                by the manufacturer if—
                                                                16                                  ‘‘(A) the expiration date extension is in-
                                                                17                         tended to support the United States ability to
                                                                18                         protect—
                                                                19                                          ‘‘(i) the public health; or
                                                                20                                          ‘‘(ii) military preparedness and effec-
                                                                21                                  tiveness; and
                                                                22                                  ‘‘(B) the expiration date extension is sup-
                                                                23                         ported by an appropriate scientific evaluation
tkelley on DSK3SPTVN1PROD with                                  24                         that is conducted or accepted by the Secretary.
                                                                             HR 307 RFS

                                                                                                                       60
                                                                  1                        ‘‘(2) REQUIREMENTS                          AND CONDITIONS.—Any
                                                                  2               extension of an expiration date under paragraph (1)
                                                                  3               shall, as part of the extension, identify—
                                                                  4                                 ‘‘(A) each specific lot, batch, or other unit
                                                                  5                        of the product for which extended expiration is
                                                                  6                        authorized;
                                                                  7                                 ‘‘(B) the duration of the extension; and
                                                                  8                                 ‘‘(C) any other requirements or conditions
                                                                  9                        as the Secretary may deem appropriate for the
                                                                10                         protection of the public health, which may in-
                                                                11                         clude requirements for, or conditions on, prod-
                                                                12                         uct sampling, storage, packaging or repack-
                                                                13                         aging, transport, labeling, notice to product re-
                                                                14                         cipients, recordkeeping, periodic testing or re-
                                                                15                         testing, or product disposition.
                                                                16                         ‘‘(3) EFFECT.—Notwithstanding any other pro-
                                                                17                vision of this Act or the Public Health Service Act,
                                                                18                an eligible product shall not be considered an unap-
                                                                19                proved product (as defined in section 564(a)(2)(A))
                                                                20                and shall not be deemed adulterated or misbranded
                                                                21                under this Act because, with respect to such prod-
                                                                22                uct, the Secretary has, under paragraph (1), ex-
                                                                23                tended the expiration date and authorized the intro-
tkelley on DSK3SPTVN1PROD with                                  24                duction or delivery for introduction into interstate
                                                                             HR 307 RFS

                                                                                                                       61
                                                                  1               commerce of such product after the expiration date
                                                                  2               provided by the manufacturer.
                                                                  3                        ‘‘(4) EXPIRATION                  DATE.—For               purposes of this
                                                                  4               subsection, the term ‘expiration date’ means the
                                                                  5               date established through appropriate stability testing
                                                                  6               required by the regulations issued by the Secretary
                                                                  7               to ensure that the product meets applicable stand-
                                                                  8               ards of identity, strength, quality, and purity at the
                                                                  9               time of use.
                                                                10                ‘‘(c) CURRENT GOOD MANUFACTURING PRACTICE.—
                                                                11                         ‘‘(1) IN        GENERAL.—The                     Secretary may, when
                                                                12                the circumstances of a domestic, military, or public
                                                                13                health emergency or material threat described in
                                                                14                subsection (a)(1)(C) so warrant, authorize, with re-
                                                                15                spect to an eligible product, deviations from current
                                                                16                good manufacturing practice requirements otherwise
                                                                17                applicable to the manufacture, processing, packing,
                                                                18                or holding of products subject to regulation under
                                                                19                this Act, including requirements under section 501
                                                                20                or 520(f)(1) or applicable conditions prescribed with
                                                                21                respect to the eligible product by an order under sec-
                                                                22                tion 520(f)(2).
                                                                23                         ‘‘(2) EFFECT.—Notwithstanding any other pro-
tkelley on DSK3SPTVN1PROD with                                  24                vision of this Act or the Public Health Service Act,
                                                                25                an eligible product shall not be considered an unap-


                                                                             HR 307 RFS

                                                                                                                       62
                                                                  1               proved product (as defined in section 564(a)(2)(A))
                                                                  2               and shall not be deemed adulterated or misbranded
                                                                  3               under this Act because, with respect to such prod-
                                                                  4               uct, the Secretary has authorized deviations from
                                                                  5               current good manufacturing practices under para-
                                                                  6               graph (1).
                                                                  7               ‘‘(d) EMERGENCY DISPENSING.—The requirements
                                                                  8 of sections 503(b) and 520(e) shall not apply to an eligible
                                                                  9 product, and the product shall not be considered an unap-
                                                                10 proved product (as defined in section 564(a)(2)(A)) and
                                                                11 shall not be deemed adulterated or misbranded under this
                                                                12 Act because it is dispensed without an individual prescrip-
                                                                13 tion, if—
                                                                14                         ‘‘(1) the product is dispensed during the cir-
                                                                15                cumstances described in subsection (a)(1)(C); and
                                                                16                         ‘‘(2) such dispensing without an individual pre-
                                                                17                scription occurs—
                                                                18                                  ‘‘(A) as permitted under the law of the
                                                                19                         State in which the product is dispensed; or
                                                                20                                  ‘‘(B) in accordance with an order issued by
                                                                21                         the Secretary, for the purposes and duration of
                                                                22                         the       circumstances                 described               in      subsection
                                                                23                         (a)(1)(C).
                                                                24                ‘‘(e) EMERGENCY USE INSTRUCTIONS.—
tkelley on DSK3SPTVN1PROD with




                                                                             HR 307 RFS

                                                                                                                       63
                                                                  1                        ‘‘(1) IN             GENERAL.—The                     Secretary, acting
                                                                  2               through an appropriate official within the Depart-
                                                                  3               ment of Health and Human Services, may create
                                                                  4               and issue emergency use instructions to inform
                                                                  5               health care providers or individuals to whom an eli-
                                                                  6               gible product is to be administered concerning such
                                                                  7               product’s approved, licensed, or cleared conditions of
                                                                  8               use.
                                                                  9                        ‘‘(2) EFFECT.—Notwithstanding any other pro-
                                                                10                visions of this Act or the Public Health Service Act,
                                                                11                a product shall not be considered an unapproved
                                                                12                product and shall not be deemed adulterated or mis-
                                                                13                branded under this Act because of the issuance of
                                                                14                emergency use instructions under paragraph (1)
                                                                15                with respect to such product or the introduction or
                                                                16                delivery for introduction of such product into inter-
                                                                17                state commerce accompanied by such instructions—
                                                                18                                  ‘‘(A) during an emergency response to an
                                                                19                         actual emergency that is the basis for a deter-
                                                                20                         mination described in subsection (a)(1)(C)(i); or
                                                                21                                  ‘‘(B) by a government entity (including a
                                                                22                         Federal, State, local, or tribal government enti-
                                                                23                         ty), or a person acting on behalf of such a gov-
tkelley on DSK3SPTVN1PROD with                                  24                         ernment entity, in preparation for an emer-
                                                                25                         gency response.’’.


                                                                             HR 307 RFS

                                                                  1               (c) RISK EVALUATION                  64       AND       MITIGATION STRATE-
                                                                  2     GIES.—Section                 505–1 of the Federal Food, Drug, and
                                                                  3 Cosmetic Act (21 U.S.C. 355–1), is amended—
                                                                  4                        (1) in subsection (f), by striking paragraph (7);
                                                                  5               and
                                                                  6                        (2) by adding at the end the following:
                                                                  7               ‘‘(k) WAIVER             IN    PUBLIC HEALTH EMERGENCIES.—
                                                                  8 The Secretary may waive any requirement of this section
                                                                  9 with respect to a qualified countermeasure (as defined in
                                                                10 section 319F–1(a)(2) of the Public Health Service Act)
                                                                11 to which a requirement under this section has been ap-
                                                                12 plied, if the Secretary determines that such waiver is re-
                                                                13 quired to mitigate the effects of, or reduce the severity
                                                                14 of, the circumstances under which—
                                                                15                         ‘‘(1) a determination described in subparagraph
                                                                16                (A), (B), or (C) of section 564(b)(1) has been made
                                                                17                by the Secretary of Homeland Security, the Sec-
                                                                18                retary of Defense, or the Secretary, respectively; or
                                                                19                         ‘‘(2) the identification of a material threat de-
                                                                20                scribed in subparagraph (D) of section 564(b)(1)
                                                                21                has been made pursuant to section 319F–2 of the
                                                                22                Public Health Service Act.’’.
                                                                23                (d) PRODUCTS HELD                         FOR        EMERGENCY USE.—The
tkelley on DSK3SPTVN1PROD with                                  24 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301
                                                                             HR 307 RFS

                                                                                                                       65
                                                                  1 et seq.) is amended by inserting after section 564A, as
                                                                  2 added by subsection (b), the following:
                                                                  3     ‘‘SEC. 564B. PRODUCTS HELD FOR EMERGENCY USE.

                                                                  4               ‘‘It is not a violation of any section of this Act or
                                                                  5 of the Public Health Service Act for a government entity
                                                                  6 (including a Federal, State, local, or tribal government en-
                                                                  7 tity), or a person acting on behalf of such a government
                                                                  8 entity, to introduce into interstate commerce a product (as
                                                                  9 defined in section 564(a)(4)) intended for emergency use,
                                                                10 if that product—
                                                                11                         ‘‘(1) is intended to be held and not used; and
                                                                12                         ‘‘(2) is held and not used, unless and until that
                                                                13                product—
                                                                14                                  ‘‘(A) is approved, cleared, or licensed
                                                                15                         under section 505, 510(k), or 515 of this Act
                                                                16                         or section 351 of the Public Health Service Act;
                                                                17                                  ‘‘(B) is authorized for investigational use
                                                                18                         under section 505 or 520 of this Act or section
                                                                19                         351 of the Public Health Service Act; or
                                                                20                                  ‘‘(C) is authorized for use under section
                                                                21                         564.’’.
                                                                22      SEC. 303. DEFINITIONS.
                                                                23                Section 565 of the Federal Food, Drug, and Cosmetic
tkelley on DSK3SPTVN1PROD with                                  24 Act (21 U.S.C. 360bbb–4) is amended by striking ‘‘The
                                                                25 Secretary, in consultation’’ and inserting the following:


                                                                             HR 307 RFS

                                                                                                                       66
                                                                  1               ‘‘(a) DEFINITIONS.—In this section—
                                                                  2                        ‘‘(1) the term ‘countermeasure’ means a quali-
                                                                  3               fied countermeasure, a security countermeasure, and
                                                                  4               a qualified pandemic or epidemic product;
                                                                  5                        ‘‘(2) the term ‘qualified countermeasure’ has
                                                                  6               the meaning given such term in section 319F–1 of
                                                                  7               the Public Health Service Act;
                                                                  8                        ‘‘(3) the term ‘security countermeasure’ has the
                                                                  9               meaning given such term in section 319F–2 of such
                                                                10                Act; and
                                                                11                         ‘‘(4) the term ‘qualified pandemic or epidemic
                                                                12                product’ means a product that meets the definition
                                                                13                given such term in section 319F–3 of the Public
                                                                14                Health Service Act and—
                                                                15                                  ‘‘(A) that has been identified by the De-
                                                                16                         partment of Health and Human Services or the
                                                                17                         Department of Defense as receiving funding di-
                                                                18                         rectly related to addressing chemical, biological,
                                                                19                         radiological, or nuclear threats, including pan-
                                                                20                         demic influenza; or
                                                                21                                  ‘‘(B) is included under this paragraph pur-
                                                                22                         suant to a determination by the Secretary.
                                                                23                ‘‘(b) GENERAL DUTIES.—The Secretary, in consulta-
tkelley on DSK3SPTVN1PROD with                                  24 tion’’.
                                                                             HR 307 RFS

                                                                  1     SEC. 304. ENHANCING MEDICAL COUNTERMEASURE AC- 67
                                                                  2                             TIVITIES.
                                                                  3               Section 565 of the Federal Food, Drug, and Cosmetic
                                                                  4 Act (21 U.S.C. 360bbb–4), as amended by section 303,
                                                                  5 is further amended—
                                                                  6                        (1) in the section heading, by striking ‘‘TECH-
                                                                  7               NICAL ASSISTANCE’’                           and inserting ‘‘COUNTER-
                                                                  8               MEASURE DEVELOPMENT, REVIEW, AND TECH-
                                                                  9               NICAL ASSISTANCE’’;
                                                                10                         (2) in subsection (b), by striking the subsection
                                                                11                enumerator and all that follows through ‘‘shall es-
                                                                12                tablish’’ and inserting the following:
                                                                13                ‘‘(b) GENERAL DUTIES.—In order to accelerate the
                                                                14 development, stockpiling, approval, licensure, and clear-
                                                                15 ance of qualified countermeasures, security counter-
                                                                16 measures, and qualified pandemic or epidemic products,
                                                                17 the Secretary, in consultation with the Assistant Secretary
                                                                18 for Preparedness and Response, shall—
                                                                19                         ‘‘(1) ensure the appropriate involvement of
                                                                20                Food and Drug Administration personnel in inter-
                                                                21                agency activities related to countermeasure advanced
                                                                22                research and development, consistent with sections
                                                                23                319F, 319F–1, 319F–2, 319F–3, 319L, and 2811
tkelley on DSK3SPTVN1PROD with                                  24                of the Public Health Service Act;
                                                                25                         ‘‘(2) ensure the appropriate involvement and
                                                                26                consultation of Food and Drug Administration per-
                                                                             HR 307 RFS

                                                                                                                       68
                                                                  1               sonnel in any flexible manufacturing activities car-
                                                                  2               ried out under section 319L of the Public Health
                                                                  3               Service Act, including with respect to meeting regu-
                                                                  4               latory requirements set forth in this Act;
                                                                  5                        ‘‘(3) promote countermeasure expertise within
                                                                  6               the Food and Drug Administration by—
                                                                  7                                 ‘‘(A) ensuring that Food and Drug Admin-
                                                                  8                        istration personnel involved in reviewing coun-
                                                                  9                        termeasures for approval, licensure, or clear-
                                                                10                         ance are informed by the Assistant Secretary
                                                                11                         for Preparedness and Response on the material
                                                                12                         threat assessment conducted under section
                                                                13                         319F–2 of the Public Health Service Act for
                                                                14                         the agent or agents for which the counter-
                                                                15                         measure under review is intended;
                                                                16                                  ‘‘(B) training Food and Drug Administra-
                                                                17                         tion personnel regarding review of counter-
                                                                18                         measures for approval, licensure, or clearance;
                                                                19                                  ‘‘(C) holding public meetings at least twice
                                                                20                         annually to encourage the exchange of scientific
                                                                21                         ideas; and
                                                                22                                  ‘‘(D) establishing protocols to ensure that
                                                                23                         countermeasure reviewers have sufficient train-
tkelley on DSK3SPTVN1PROD with                                  24                         ing or experience with countermeasures;
                                                                             HR 307 RFS

                                                                                                                       69
                                                                  1                        ‘‘(4) maintain teams, composed of Food and
                                                                  2               Drug Administration personnel with expertise on
                                                                  3               countermeasures,                         including             specific          counter-
                                                                  4               measures, populations with special clinical needs (in-
                                                                  5               cluding children and pregnant women that may use
                                                                  6               countermeasures, as applicable and appropriate),
                                                                  7               classes or groups of countermeasures, or other coun-
                                                                  8               termeasure-related technologies and capabilities, that
                                                                109               shall—          ‘‘(A) consult with countermeasure experts,
                                                                11                         including countermeasure sponsors and appli-
                                                                12                         cants, to identify and help resolve scientific
                                                                13                         issues related to the approval, licensure, or
                                                                14                         clearance of countermeasures, through work-
                                                                15                         shops or public meetings; and
                                                                16                                  ‘‘(B) improve and advance the science re-
                                                                17                         lating to the development of new tools, stand-
                                                                18                         ards, and approaches to assessing and evalu-
                                                                19                         ating countermeasures—
                                                                20                                          ‘‘(i) in order to inform the process for
                                                                21                                  countermeasure approval, clearance, and li-
                                                                22                                  censure; and
                                                                23                                          ‘‘(ii) with respect to the development
tkelley on DSK3SPTVN1PROD with                                  24                                  of countermeasures for populations with
                                                                25                                  special clinical needs, including children


                                                                             HR 307 RFS

                                                                                                                       70
                                                                  1                                 and pregnant women, in order to meet the
                                                                  2                                 needs of such populations, as necessary
                                                                  3                                 and appropriate; and
                                                                  4                        ‘‘(5) establish’’; and
                                                                  5                        (3) by adding at the end the following:
                                                                  6               ‘‘(c) FINAL GUIDANCE                        ON       DEVELOPMENT                OF   ANI-
                                                                  7     MAL       MODELS.—
                                                                  8                        ‘‘(1) IN       GENERAL.—Not                    later than 1 year after
                                                                  9               the date of the enactment of the Pandemic and All-
                                                                10                Hazards Preparedness Reauthorization Act of 2013,
                                                                11                the Secretary shall provide final guidance to indus-
                                                                12                try regarding the development of animal models to
                                                                13                support approval, clearance, or licensure of counter-
                                                                14                measures referred to in subsection (a) when human
                                                                15                efficacy studies are not ethical or feasible.
                                                                16                         ‘‘(2) AUTHORITY                  TO EXTEND DEADLINE.—The
                                                                17                Secretary may extend the deadline for providing
                                                                18                final guidance under paragraph (1) by not more
                                                                19                than 6 months upon submission by the Secretary of
                                                                20                a report on the status of such guidance to the Com-
                                                                21                mittee on Energy and Commerce of the House of
                                                                22                Representatives and the Committee on Health, Edu-
                                                                23                cation, Labor, and Pensions of the Senate.
                                                                24                ‘‘(d) DEVELOPMENT                        AND     ANIMAL MODELING PRO-
tkelley on DSK3SPTVN1PROD with



                                                                25      CEDURES.—
                                                                             HR 307 RFS

                                                                  1                        ‘‘(1) AVAILABILITY      71            OF ANIMAL MODEL MEET-
                                                                  2               INGS.—To             facilitate the timely development of ani-
                                                                  3               mal models and support the development, stock-
                                                                  4               piling, licensure, approval, and clearance of counter-
                                                                  5               measures, the Secretary shall, not later than 180
                                                                  6               days after the enactment of this subsection, establish
                                                                  7               a procedure by which a sponsor or applicant that is
                                                                  8               developing a countermeasure for which human effi-
                                                                  9               cacy studies are not ethical or practicable, and that
                                                                10                has an approved investigational new drug application
                                                                11                or investigational device exemption, may request and
                                                                12                receive—
                                                                13                                  ‘‘(A) a meeting to discuss proposed animal
                                                                14                         model development activities; and
                                                                15                                  ‘‘(B) a meeting prior to initiating pivotal
                                                                16                         animal studies.
                                                                17                         ‘‘(2) PEDIATRIC                 MODELS.—To               facilitate the de-
                                                                18                velopment and selection of animal models that could
                                                                19                translate to pediatric studies, any meeting conducted
                                                                20                under paragraph (1) shall include discussion of ani-
                                                                21                mal models for pediatric populations, as appropriate.
                                                                22                ‘‘(e)       REVIEW             AND          APPROVAL                OF          COUNTER-
                                                                23      MEASURES.—

tkelley on DSK3SPTVN1PROD with                                  24                         ‘‘(1) MATERIAL                  THREAT.—When                    evaluating an
                                                                25                application or submission for approval, licensure, or


                                                                             HR 307 RFS

                                                                                                                       72
                                                                  1               clearance of a countermeasure, the Secretary shall
                                                                  2               take into account the material threat posed by the
                                                                  3               chemical, biological, radiological, or nuclear agent or
                                                                  4               agents identified under section 319F–2 of the Public
                                                                  5               Health Service Act for which the countermeasure
                                                                  6               under review is intended.
                                                                  7                        ‘‘(2) REVIEW                EXPERTISE.—When                            practicable
                                                                  8               and appropriate, teams of Food and Drug Adminis-
                                                                  9               tration personnel reviewing applications or submis-
                                                                10                sions described under paragraph (1) shall include a
                                                                11                reviewer with sufficient training or experience with
                                                                12                countermeasures pursuant to the protocols estab-
                                                                13                lished under subsection (b)(3)(D).’’.
                                                                14      SEC. 305. REGULATORY MANAGEMENT PLANS.
                                                                15                Section 565 of the Federal Food, Drug, and Cosmetic
                                                                16 Act (21 U.S.C. 360bbb–4), as amended by section 304,
                                                                17 is further amended by adding at the end the following:
                                                                18                ‘‘(f) REGULATORY MANAGEMENT PLAN.—
                                                                19                         ‘‘(1) DEFINITION.—In this subsection, the term
                                                                20                ‘eligible countermeasure’ means—
                                                                21                                  ‘‘(A) a security countermeasure with re-
                                                                22                         spect to which the Secretary has entered into a
                                                                23                         procurement contract under section 319F–2(c)
tkelley on DSK3SPTVN1PROD with                                  24                         of the Public Health Service Act; or
                                                                             HR 307 RFS

                                                                                                                       73
                                                                  1                                 ‘‘(B) a countermeasure with respect to
                                                                  2                        which the Biomedical Advanced Research and
                                                                  3                        Development Authority has provided funding
                                                                  4                        under section 319L of the Public Health Serv-
                                                                  5                        ice Act for advanced research and development.
                                                                  6                        ‘‘(2) REGULATORY                     MANAGEMENT PLAN PROC-
                                                                  7               ESS.—The             Secretary, in consultation with the As-
                                                                  8               sistant Secretary for Preparedness and Response
                                                                  9               and the Director of the Biomedical Advanced Re-
                                                                10                search and Development Authority, shall establish a
                                                                11                formal process for obtaining scientific feedback and
                                                                12                interactions regarding the development and regu-
                                                                13                latory review of eligible countermeasures by facili-
                                                                14                tating the development of written regulatory man-
                                                                15                agement plans in accordance with this subsection.
                                                                16                         ‘‘(3) SUBMISSION                  OF REQUEST AND PROPOSED
                                                                17                PLAN BY SPONSOR OR APPLICANT.—
                                                                18                                  ‘‘(A) IN         GENERAL.—A                   sponsor or appli-
                                                                19                         cant of an eligible countermeasure may initiate
                                                                20                         the process described under paragraph (2) upon
                                                                21                         submission of a written request to the Sec-
                                                                22                         retary. Such request shall include a proposed
                                                                23                         regulatory management plan.
tkelley on DSK3SPTVN1PROD with                                  24                                  ‘‘(B) TIMING              OF SUBMISSION.—A                    sponsor
                                                                25                         or applicant may submit a written request


                                                                             HR 307 RFS

                                                                                                                       74
                                                                  1                        under subparagraph (A) after the eligible coun-
                                                                  2                        termeasure has an investigational new drug or
                                                                  3                        investigational device exemption in effect.
                                                                  4                                 ‘‘(C)       RESPONSE                 BY      SECRETARY.—The
                                                                  5                        Secretary shall direct the Food and Drug Ad-
                                                                  6                        ministration, upon submission of a written re-
                                                                  7                        quest by a sponsor or applicant under subpara-
                                                                  8                        graph (A), to work with the sponsor or appli-
                                                                  9                        cant to agree on a regulatory management plan
                                                                10                         within a reasonable time not to exceed 90 days.
                                                                11                         If the Secretary determines that no plan can be
                                                                12                         agreed upon, the Secretary shall provide to the
                                                                13                         sponsor or applicant, in writing, the scientific
                                                                14                         or regulatory rationale why such agreement
                                                                15                         cannot be reached.
                                                                16                         ‘‘(4) PLAN.—The content of a regulatory man-
                                                                17                agement plan agreed to by the Secretary and a spon-
                                                                18                sor or applicant shall include—
                                                                19                                  ‘‘(A) an agreement between the Secretary
                                                                20                         and the sponsor or applicant regarding develop-
                                                                21                         mental milestones that will trigger responses by
                                                                22                         the Secretary as described in subparagraph (B);
                                                                23                                  ‘‘(B) performance targets and goals for
tkelley on DSK3SPTVN1PROD with                                  24                         timely and appropriate responses by the Sec-
                                                                25                         retary to the triggers described under subpara-


                                                                             HR 307 RFS

                                                                                                                       75
                                                                  1                        graph (A), including meetings between the Sec-
                                                                  2                        retary and the sponsor or applicant, written
                                                                  3                        feedback, decisions by the Secretary, and other
                                                                  4                        activities carried out as part of the development
                                                                  5                        and review process; and
                                                                  6                                 ‘‘(C) an agreement on how the plan shall
                                                                  7                        be modified, if needed.
                                                                  8                        ‘‘(5) MILESTONES                      AND        PERFORMANCE           TAR-
                                                                  9               GETS.—The               developmental milestones described in
                                                                10                paragraph (4)(A) and the performance targets and
                                                                11                goals described in paragraph (4)(B) shall include—
                                                                12                                  ‘‘(A) feedback from the Secretary regard-
                                                                13                         ing the data required to support the approval,
                                                                14                         clearance, or licensure of the eligible counter-
                                                                15                         measure involved;
                                                                16                                  ‘‘(B) feedback from the Secretary regard-
                                                                17                         ing the data necessary to inform any authoriza-
                                                                18                         tion under section 564;
                                                                19                                  ‘‘(C) feedback from the Secretary regard-
                                                                20                         ing the data necessary to support the posi-
                                                                21                         tioning and delivery of the eligible counter-
                                                                22                         measure, including to the Strategic National
                                                                23                         Stockpile;
tkelley on DSK3SPTVN1PROD with                                  24                                  ‘‘(D) feedback from the Secretary regard-
                                                                25                         ing the data necessary to support the submis-


                                                                             HR 307 RFS

                                                                                                                       76
                                                                  1                        sion of protocols for review under section
                                                                  2                        505(b)(5)(B);
                                                                  3                                 ‘‘(E) feedback from the Secretary regard-
                                                                  4                        ing any gaps in scientific knowledge that will
                                                                  5                        need resolution prior to approval, licensure, or
                                                                  6                        clearance of the eligible countermeasure and
                                                                  7                        plans for conducting the necessary scientific re-
                                                                  8                        search;
                                                                  9                                 ‘‘(F) identification of the population for
                                                                10                         which the countermeasure sponsor or applicant
                                                                11                         seeks approval, licensure, or clearance and the
                                                                12                         population for which desired labeling would not
                                                                13                         be appropriate, if known; and
                                                                14                                  ‘‘(G) as necessary and appropriate, and to
                                                                15                         the extent practicable, a plan for demonstrating
                                                                16                         safety and effectiveness in pediatric popu-
                                                                17                         lations, and for developing pediatric dosing, for-
                                                                18                         mulation, and administration with respect to
                                                                19                         the eligible countermeasure, provided that such
                                                                20                         plan would not delay authorization under sec-
                                                                21                         tion 564, approval, licensure, or clearance for
                                                                22                         adults.
                                                                23                         ‘‘(6) PRIORITIZATION.—
                                                                24                                  ‘‘(A) PLANS                 FOR        SECURITY               COUNTER-
tkelley on DSK3SPTVN1PROD with



                                                                25                         MEASURES.—The                     Secretary shall establish reg-
                                                                             HR 307 RFS

                                                                                                                       77
                                                                  1                        ulatory management plans for all security coun-
                                                                  2                        termeasures for which a request is submitted
                                                                  3                        under paragraph (3)(A).
                                                                  4                                 ‘‘(B) PLANS             FOR OTHER ELIGIBLE COUN-
                                                                  5                        TERMEASURES.—The                        Secretary shall determine
                                                                  6                        whether resources are available to establish reg-
                                                                  7                        ulatory management plans for eligible counter-
                                                                  8                        measures             that        are        not       security         counter-
                                                                  9                        measures. If resources are available to establish
                                                                10                         regulatory management plans for eligible coun-
                                                                11                         termeasures that are not security counter-
                                                                12                         measures, and if resources are not available to
                                                                13                         establish regulatory management plans for all
                                                                14                         eligible countermeasures for which requests
                                                                15                         have been submitted, the Director of the Bio-
                                                                16                         medical Advanced Research and Development
                                                                17                         Authority, in consultation with the Commis-
                                                                18                         sioner, shall prioritize which eligible counter-
                                                                19                         measures may receive regulatory management
                                                                20                         plans.’’.
                                                                21      SEC. 306. REPORT.
                                                                22                Section 565 of the Federal Food, Drug, and Cosmetic
                                                                23 Act (21 U.S.C. 360bbb–4), as amended by section 305,
tkelley on DSK3SPTVN1PROD with                                  24 is further amended by adding at the end the following:
                                                                             HR 307 RFS

                                                                                                                       78
                                                                  1               ‘‘(g) ANNUAL REPORT.—Not later than 180 days
                                                                  2 after the date of enactment of this subsection, and annu-
                                                                  3 ally thereafter, the Secretary shall make publicly available
                                                                  4 on the Web site of the Food and Drug Administration a
                                                                  5 report that details the countermeasure development and
                                                                  6 review activities of the Food and Drug Administration, in-
                                                                  7 cluding—
                                                                  8                        ‘‘(1) with respect to the development of new
                                                                  9               tools, standards, and approaches to assess and
                                                                10                evaluate countermeasures—
                                                                11                                  ‘‘(A) the identification of the priorities of
                                                                12                         the Food and Drug Administration and the
                                                                13                         progress made on such priorities; and
                                                                14                                  ‘‘(B) the identification of scientific gaps
                                                                15                         that impede the development, approval, licen-
                                                                16                         sure, or clearance of countermeasures for popu-
                                                                17                         lations with special clinical needs, including
                                                                18                         children and pregnant women, and the progress
                                                                19                         made on resolving these challenges;
                                                                20                         ‘‘(2) with respect to countermeasures for which
                                                                21                a regulatory management plan has been agreed upon
                                                                22                under subsection (f), the extent to which the per-
                                                                23                formance targets and goals set forth in subsection
tkelley on DSK3SPTVN1PROD with                                  24                (f)(4)(B) and the regulatory management plan have
                                                                25                been met, including, for each such countermeasure—


                                                                             HR 307 RFS

                                                                                                                       79
                                                                  1                                 ‘‘(A) whether the regulatory management
                                                                  2                        plan was completed within the required time-
                                                                  3                        frame, and the length of time taken to complete
                                                                  4                        such plan;
                                                                  5                                 ‘‘(B) whether the Secretary adhered to the
                                                                  6                        timely and appropriate response times set forth
                                                                  7                        in such plan; and
                                                                  8                                 ‘‘(C) explanations for any failure to meet
                                                                  9                        such performance targets and goals;
                                                                10                         ‘‘(3) the number of regulatory teams estab-
                                                                11                lished pursuant to subsection (b)(4), the number of
                                                                12                products, classes of products, or technologies as-
                                                                13                signed to each such team, and the number of, type
                                                                14                of, and any progress made as a result of consulta-
                                                                15                tions carried out under subsection (b)(4)(A);
                                                                16                         ‘‘(4) an estimate of resources obligated to coun-
                                                                17                termeasure development and regulatory assessment,
                                                                18                including—
                                                                19                                  ‘‘(A) Center-specific objectives and accom-
                                                                20                         plishments; and
                                                                21                                  ‘‘(B) the number of full-time equivalent
                                                                22                         employees of the Food and Drug Administra-
                                                                23                         tion who directly support the review of counter-
tkelley on DSK3SPTVN1PROD with                                  24                         measures;
                                                                             HR 307 RFS

                                                                                                                       80
                                                                  1                        ‘‘(5) the number of countermeasure applications
                                                                  2               and submissions submitted, the number of counter-
                                                                  3               measures approved, licensed, or cleared, the status
                                                                  4               of remaining submitted applications and submis-
                                                                  5               sions, and the number of each type of authorization
                                                                  6               issued pursuant to section 564;
                                                                  7                        ‘‘(6) the number of written requests for a regu-
                                                                  8               latory management plan submitted under subsection
                                                                  9               (f)(3)(A), the number of regulatory management
                                                                10                plans developed, and the number of such plans de-
                                                                11                veloped for security countermeasures; and
                                                                12                         ‘‘(7) the number, type, and frequency of meet-
                                                                13                ings between the Food and Drug Administration
                                                                14                and—
                                                                15                                  ‘‘(A) sponsors of a countermeasure as de-
                                                                16                         fined in subsection (a); or
                                                                17                                  ‘‘(B) another agency engaged in develop-
                                                                18                         ment or management of portfolios for such
                                                                19                         countermeasures, including the Centers for Dis-
                                                                20                         ease Control and Prevention, the Biomedical
                                                                21                         Advanced Research and Development Authority,
                                                                22                         the National Institutes of Health, and the ap-
                                                                23                         propriate agencies of the Department of De-
tkelley on DSK3SPTVN1PROD with                                  24                         fense.’’.
                                                                             HR 307 RFS

                                                                  1     SEC. 307. PEDIATRIC MEDICAL COUNTERMEASURES.   81
                                                                  2               (a) PEDIATRIC STUDIES                          OF     DRUGS.—Section 505A
                                                                  3 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
                                                                  4 355a) is amended—
                                                                  5                        (1) in subsection (d), by adding at the end the
                                                                  6               following:
                                                                  7                        ‘‘(5) CONSULTATION.—With respect to a drug
                                                                  8               that is a qualified countermeasure (as defined in sec-
                                                                  9               tion 319F–1 of the Public Health Service Act), a se-
                                                                10                curity countermeasure (as defined in section 319F–
                                                                11                2 of the Public Health Service Act), or a qualified
                                                                12                pandemic or epidemic product (as defined in section
                                                                13                319F–3 of the Public Health Service Act), the Sec-
                                                                14                retary shall solicit input from the Assistant Sec-
                                                                15                retary for Preparedness and Response regarding the
                                                                16                need for and, from the Director of the Biomedical
                                                                17                Advanced Research and Development Authority re-
                                                                18                garding the conduct of, pediatric studies under this
                                                                19                section.’’; and
                                                                20                         (2) in subsection (n)(1), by adding at the end
                                                                21                the following:
                                                                22                                  ‘‘(C) For a drug that is a qualified coun-
                                                                23                         termeasure (as defined in section 319F–1 of the
tkelley on DSK3SPTVN1PROD with                                  24                         Public Health Service Act), a security counter-
                                                                25                         measure (as defined in section 319F–2 of the
                                                                26                         Public Health Service Act), or a qualified pan-
                                                                             HR 307 RFS

                                                                                                                       82
                                                                  1                        demic or epidemic product (as defined in sec-
                                                                  2                        tion 319F–3 of such Act), in addition to any
                                                                  3                        action with respect to such drug under subpara-
                                                                  4                        graph (A) or (B), the Secretary shall notify the
                                                                  5                        Assistant Secretary for Preparedness and Re-
                                                                  6                        sponse and the Director of the Biomedical Ad-
                                                                  7                        vanced Research and Development Authority of
                                                                  8                        all pediatric studies in the written request
                                                                  9                        issued by the Commissioner of Food and
                                                                10                         Drugs.’’.
                                                                11                (b)       ADDITION              TO        PRIORITY             LIST         CONSIDER-
                                                                12      ATIONS.—Section                   409I of the Public Health Service Act
                                                                13 (42 U.S.C. 284m) is amended—
                                                                14                         (1) by striking subsection (a)(2) and inserting
                                                                15                the following:
                                                                16                         ‘‘(2) CONSIDERATION                         OF AVAILABLE INFORMA-
                                                                17                TION.—In            developing and prioritizing the list under
                                                                18                paragraph (1), the Secretary—
                                                                19                                  ‘‘(A) shall consider—
                                                                20                                          ‘‘(i) therapeutic gaps in pediatrics
                                                                21                                  that may include developmental pharma-
                                                                22                                  cology, pharmacogenetic determinants of
                                                                23                                  drug response, metabolism of drugs and
tkelley on DSK3SPTVN1PROD with                                  24                                  biologics in children, and pediatric clinical
                                                                25                                  trials;


                                                                             HR 307 RFS

                                                                                                                       83
                                                                  1                                         ‘‘(ii) particular pediatric diseases, dis-
                                                                  2                                 orders or conditions where more complete
                                                                  3                                 knowledge and testing of therapeutics, in-
                                                                  4                                 cluding drugs and biologics, may be bene-
                                                                  5                                 ficial in pediatric populations; and
                                                                  6                                         ‘‘(iii) the adequacy of necessary infra-
                                                                  7                                 structure to conduct pediatric pharma-
                                                                  8                                 cological research, including research net-
                                                                  9                                 works and trained pediatric investigators;
                                                                10                                  and
                                                                11                                  ‘‘(B) may consider the availability of quali-
                                                                12                         fied countermeasures (as defined in section
                                                                13                         319F–1), security countermeasures (as defined
                                                                14                         in section 319F–2), and qualified pandemic or
                                                                15                         epidemic products (as defined in section 319F–
                                                                16                         3) to address the needs of pediatric populations,
                                                                17                         in consultation with the Assistant Secretary for
                                                                18                         Preparedness and Response, consistent with the
                                                                19                         purposes of this section.’’; and
                                                                20                         (2) in subsection (b), by striking ‘‘subsection
                                                                21                (a)’’ and inserting ‘‘paragraphs (1) and (2)(A) of
                                                                22                subsection (a)’’.
                                                                23                (c) ADVICE            AND      RECOMMENDATIONS                           OF THE   PEDI-
                                                                24      ATRIC            ADVISORY COMMITTEE REGARDING COUNTER-
tkelley on DSK3SPTVN1PROD with



                                                                25      MEASURES FOR                     PEDIATRIC POPULATIONS.—Subsection
                                                                             HR 307 RFS

                                                                                                                       84
                                                                  1 (b)(2) of section 14 of the Best Pharmaceuticals for Chil-
                                                                  2 dren Act (42 U.S.C. 284m note) is amended—
                                                                  3                        (1) in subparagraph (C), by striking the period
                                                                  4               and inserting ‘‘; and’’; and
                                                                  5                        (2) by adding at the end the following:
                                                                  6                                 ‘‘(D) the development of countermeasures
                                                                  7                        (as defined in section 565(a) of the Federal
                                                                  8                        Food, Drug, and Cosmetic Act) for pediatric
                                                                  9                        populations.’’.
                                                                10      TITLE IV—ACCELERATING MED-
                                                                11         ICAL COUNTERMEASURE AD-
                                                                12         VANCED RESEARCH AND DE-
                                                                13         VELOPMENT
                                                                14      SEC. 401. BIOSHIELD.

                                                                15                (a) PROCUREMENT                          OF    COUNTERMEASURES.—Sec-
                                                                16 tion 319F–2(c) of the Public Health Service Act (42
                                                                17 U.S.C. 247d–6b(c)) is amended—
                                                                18                         (1) in paragraph (1)(B)(i)(III)(bb), by striking
                                                                19                ‘‘eight years’’ and inserting ‘‘10 years’’;
                                                                20                         (2) in paragraph (2)(C), by striking ‘‘the des-
                                                                21                ignated congressional committees (as defined in
                                                                22                paragraph (10))’’ and inserting ‘‘the appropriate
                                                                23                committees of Congress’’;
tkelley on DSK3SPTVN1PROD with                                  24                         (3) in paragraph (5)(B)(ii), by striking ‘‘eight
                                                                25                years’’ and inserting ‘‘10 years’’;


                                                                             HR 307 RFS

                                                                                                                       85
                                                                  1                        (4) in subparagraph (C) of paragraph (6)—
                                                                  2                                 (A) in the subparagraph heading, by strik-
                                                                  3                        ing ‘‘DESIGNATED                      CONGRESSIONAL                     COMMIT-
                                                                  4                        TEES’’       and inserting ‘‘APPROPRIATE                               CONGRES-
                                                                  5                        SIONAL COMMITTEES’’;                        and
                                                                  6                                 (B) by striking ‘‘the designated congres-
                                                                  7                        sional committees’’ and inserting ‘‘the appro-
                                                                  8                        priate congressional committees’’; and
                                                                  9                        (5) in paragraph (7)(C)—
                                                                10                                  (A) in clause (i)(I), by inserting ‘‘including
                                                                11                         advanced research and development,’’ after ‘‘as
                                                                12                         may reasonably be required,’’;
                                                                13                                  (B) in clause (ii)—
                                                                14                                          (i) in subclause (III), by striking
                                                                15                                  ‘‘eight years’’ and inserting ‘‘10 years’’;
                                                                16                                  and
                                                                17                                          (ii) by striking subclause (IX) and in-
                                                                18                                  serting the following:
                                                                19                                                   ‘‘(IX) CONTRACT                       TERMS.—The
                                                                20                                          Secretary, in any contract for procure-
                                                                21                                          ment under this section—
                                                                22                                                            ‘‘(aa) may specify—
                                                                23                                                                     ‘‘(AA) the dosing and
tkelley on DSK3SPTVN1PROD with                                  24                                                            administration requirements
                                                                             HR 307 RFS

                                                                                                                       86
                                                                  1                                                           for the countermeasure to be
                                                                  2                                                           developed and procured;
                                                                  3                                                                    ‘‘(BB) the amount of
                                                                  4                                                           funding that will be dedi-
                                                                  5                                                           cated by the Secretary for
                                                                  6                                                           advanced research, develop-
                                                                  7                                                           ment, and procurement of
                                                                  8                                                           the countermeasure; and
                                                                  9                                                                    ‘‘(CC) the specifications
                                                                10                                                            the        countermeasure           must
                                                                11                                                            meet to qualify for procure-
                                                                12                                                            ment under a contract under
                                                                13                                                            this section; and
                                                                14                                                            ‘‘(bb) shall provide a clear
                                                                15                                                   statement of defined Government
                                                                16                                                   purpose limited to uses related to
                                                                17                                                   a security countermeasure, as de-
                                                                18                                                   fined in paragraph (1)(B).’’; and
                                                                19                                  (C) by adding at the end the following:
                                                                20                                          ‘‘(viii) FLEXIBILITY.—In carrying out
                                                                21                                  this section, the Secretary may, consistent
                                                                22                                  with the applicable provisions of this sec-
                                                                23                                  tion, enter into contracts and other agree-
tkelley on DSK3SPTVN1PROD with                                  24                                  ments that are in the best interest of the
                                                                25                                  Government in meeting identified security


                                                                             HR 307 RFS

                                                                                                                       87
                                                                  1                                 countermeasure needs, including with re-
                                                                  2                                 spect to reimbursement of the cost of ad-
                                                                  3                                 vanced research and development as a rea-
                                                                  4                                 sonable, allowable, and allocable direct cost
                                                                  5                                 of the contract involved.’’.
                                                                  6               (b) REAUTHORIZATION                          OF THE           SPECIAL RESERVE
                                                                  7 FUND.—Section 319F–2 of the Public Health Service Act
                                                                  8 (42 U.S.C. 247d–6b) is amended—
                                                                  9                        (1) in subsection (c)—
                                                                10                                  (A) by striking ‘‘special reserve fund under
                                                                11                         paragraph (10)’’ each place it appears and in-
                                                                12                         serting ‘‘special reserve fund as defined in sub-
                                                                13                         section (h)’’; and
                                                                14                                  (B) by striking paragraphs (9) and (10);
                                                                15                         and
                                                                16                         (2) by adding at the end the following:
                                                                17                ‘‘(g) SPECIAL RESERVE FUND.—
                                                                18                         ‘‘(1) AUTHORIZATION                         OF APPROPRIATIONS.—In
                                                                19                addition to amounts appropriated to the special re-
                                                                20                serve fund prior to the date of the enactment of this
                                                                21                subsection, there is authorized to be appropriated,
                                                                22                for the procurement of security countermeasures
                                                                23                under subsection (c) and for carrying out section
tkelley on DSK3SPTVN1PROD with                                  24                319L (relating to the Biomedical Advanced Research
                                                                25                and Development Authority), $2,800,000,000 for the


                                                                             HR 307 RFS

                                                                                                                       88
                                                                  1               period of fiscal years 2014 through 2018. Amounts
                                                                  2               appropriated pursuant to the preceding sentence are
                                                                  3               authorized to remain available until September 30,
                                                                  4               2019.
                                                                  5                        ‘‘(2) USE            OF SPECIAL RESERVE FUND FOR AD-
                                                                  6               VANCED RESEARCH AND DEVELOPMENT.—The                                                Sec-
                                                                  7               retary may utilize not more than 50 percent of the
                                                                  8               amounts authorized to be appropriated under para-
                                                                  9               graph (1) to carry out section 319L (related to the
                                                                10                Biomedical Advanced Research and Development
                                                                11                Authority). Amounts authorized to be appropriated
                                                                12                under this subsection to carry out section 319L are
                                                                13                in addition to amounts otherwise authorized to be
                                                                14                appropriated to carry out such section.
                                                                15                         ‘‘(3) RESTRICTIONS                          ON     USE          OF     FUNDS.—
                                                                16                Amounts in the special reserve fund shall not be
                                                                17                used to pay costs other than payments made by the
                                                                18                Secretary to a vendor for advanced development
                                                                19                (under section 319L) or for procurement of a secu-
                                                                20                rity countermeasure under subsection (c)(7).
                                                                21                         ‘‘(4) REPORT.—Not later than 30 days after
                                                                22                any date on which the Secretary determines that the
                                                                23                amount of funds in the special reserve fund available
tkelley on DSK3SPTVN1PROD with                                  24                for procurement is less than $1,500,000,000, the
                                                                25                Secretary shall submit to the appropriate committees


                                                                             HR 307 RFS

                                                                                                                       89
                                                                  1               of Congress a report detailing the amount of such
                                                                  2               funds available for procurement and the impact such
                                                                  3               reduction in funding will have—
                                                                  4                                 ‘‘(A) in meeting the security counter-
                                                                  5                        measure needs identified under this section; and
                                                                  6                                 ‘‘(B) on the annual Public Health Emer-
                                                                  7                        gency Medical Countermeasures Enterprise and
                                                                  8                        Strategy Implementation Plan (pursuant to sec-
                                                                  9                        tion 2811(d)).
                                                                10                ‘‘(h) DEFINITIONS.—In this section:
                                                                11                         ‘‘(1) The term ‘advanced research and develop-
                                                                12                ment’ has the meaning given such term in section
                                                                13                319L(a).
                                                                14                         ‘‘(2) The term ‘special reserve fund’ means the
                                                                15                ‘Biodefense Countermeasures’ appropriations ac-
                                                                16                count, any appropriation made available pursuant to
                                                                17                section 521(a) of the Homeland Security Act of
                                                                18                2002, and any appropriation made available pursu-
                                                                19                ant to subsection (g)(1).’’.
                                                                20      SEC. 402. BIOMEDICAL ADVANCED RESEARCH AND DEVEL-
                                                                21                              OPMENT AUTHORITY.
                                                                22                (a) DUTIES.—Section 319L(c)(4) of the Public
                                                                23 Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amend-
tkelley on DSK3SPTVN1PROD with                                  24 ed—
                                                                             HR 307 RFS

                                                                                                                       90
                                                                  1                        (1) in subparagraph (B)(iii), by inserting
                                                                  2               ‘‘(which may include advanced research and develop-
                                                                  3               ment for purposes of fulfilling requirements under
                                                                  4               the Federal Food, Drug, and Cosmetic Act or sec-
                                                                  5               tion 351 of this Act)’’ after ‘‘development’’; and
                                                                  6                        (2) in subparagraph (D)(iii), by striking ‘‘and
                                                                  7               vaccine manufacturing technologies’’ and inserting
                                                                  8               ‘‘vaccine-manufacturing technologies, dose-sparing
                                                                  9               technologies, efficacy-increasing technologies, and
                                                                10                platform technologies’’.
                                                                11                (b)               TRANSACTION                         AUTHORITIES.—Section
                                                                12 319L(c)(5) of the Public Health Service Act (42 U.S.C.
                                                                13 247d–7e(c)(5)) is amended by adding at the end the fol-
                                                                14 lowing:
                                                                15                                  ‘‘(G) GOVERNMENT                      PURPOSE.—In             award-
                                                                16                         ing contracts, grants, and cooperative agree-
                                                                17                         ments under this section, the Secretary shall
                                                                18                         provide a clear statement of defined Govern-
                                                                19                         ment purpose related to activities included in
                                                                20                         subsection (a)(6)(B) for a qualified counter-
                                                                21                         measure or qualified pandemic or epidemic
                                                                22                         product.’’.
                                                                23                (c) FUND.—Paragraph (2) of section 319L(d) of the
tkelley on DSK3SPTVN1PROD with                                  24 Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is
                                                                25 amended to read as follows:


                                                                             HR 307 RFS

                                                                                                                       91
                                                                  1                        ‘‘(2) FUNDING.—To carry out the purposes of
                                                                  2               this section, there is authorized to be appropriated
                                                                  3               to the Fund $415,000,000 for each of fiscal years
                                                                  4               2013 through 2017, such amounts to remain avail-
                                                                  5               able until expended.’’.
                                                                  6               (d) CONTINUED INAPPLICABILITY                                  OF    CERTAIN PRO-
                                                                  7     VISIONS.—Section                    319L(e)(1)(C) of the Public Health
                                                                  8 Service Act (42 U.S.C. 247d–7e(e)(1)(C)) is amended by
                                                                  9 striking ‘‘7 years’’ and inserting ‘‘11 years’’.
                                                                10                (e) EXTENSION                   OF       LIMITED ANTITRUST EXEMP-
                                                                11      TION.—

                                                                12                         (1) IN       GENERAL.—Section                       405(b) of the Pan-
                                                                13                demic and All-Hazards Preparedness Act (42 U.S.C.
                                                                14                247d–6a note) is amended by striking ‘‘6-year’’ and
                                                                15                inserting ‘‘11-year’’.
                                                                16                         (2) EFFECTIVE                   DATE.—This                subsection shall
                                                                17                take effect as if enacted on December 17, 2012.
                                                                18                (f) INDEPENDENT EVALUATION.—Section 319L of
                                                                19 the Public Health Service Act (42 U.S.C. 247d–7e) is
                                                                20 amended by adding at the end the following:
                                                                21                ‘‘(f) INDEPENDENT EVALUATION.—
                                                                22                         ‘‘(1) IN        GENERAL.—Not                     later than 180 days
                                                                23                after the date of enactment of this subsection, the
tkelley on DSK3SPTVN1PROD with                                  24                Comptroller General of the United States shall con-
                                                                25                duct an independent evaluation of the activities car-


                                                                             HR 307 RFS

                                                                                                                       92
                                                                  1               ried out to facilitate flexible manufacturing capacity
                                                                  2               pursuant to this section.
                                                                  3                        ‘‘(2) REPORT.—Not later than 1 year after the
                                                                  4               date of enactment of this subsection, the Comp-
                                                                  5               troller General of the United States shall submit to
                                                                  6               the appropriate committees of Congress a report
                                                                  7               concerning the results of the evaluation conducted
                                                                  8               under paragraph (1). Such report shall review and
                                                                109               assess—         ‘‘(A) the extent to which flexible manufac-
                                                                11                         turing capacity under this section is dedicated
                                                                12                         to chemical, biological, radiological, and nuclear
                                                                13                         threats;
                                                                14                                  ‘‘(B) the activities supported by flexible
                                                                15                         manufacturing initiatives; and
                                                                16                                  ‘‘(C) the ability of flexible manufacturing
                                                                17                         activities carried out under this section to—
                                                                18                                          ‘‘(i) secure and leverage leading tech-
                                                                19                                  nical expertise with respect to counter-
                                                                20                                  measure advanced research, development,
                                                                21                                  and manufacturing processes; and
                                                                22                                          ‘‘(ii) meet the surge manufacturing
                                                                23                                  capacity needs presented by novel and
tkelley on DSK3SPTVN1PROD with                                  24                                  emerging threats, including chemical, bio-
                                                                25                                  logical, radiological, and nuclear agents.’’.


                                                                             HR 307 RFS

                                                                  1               (g) DEFINITIONS.—                   93
                                                                  2                        (1)       QUALIFIED                 COUNTERMEASURE.—Section
                                                                  3               319F–1(a)(2)(A) of the Public Health Service Act
                                                                  4               (42 U.S.C. 247d–6a(a)(2)(A)) is amended—
                                                                  5                                 (A) in the matter preceding clause (i), by
                                                                  6                        striking ‘‘to—’’ and inserting ‘‘—’’;
                                                                  7                                 (B) in clause (i)—
                                                                  8                                         (i) by striking ‘‘diagnose’’ and insert-
                                                                  9                                 ing ‘‘to diagnose’’; and
                                                                10                                          (ii) by striking ‘‘; or’’ and inserting a
                                                                11                                  semicolon;
                                                                12                                  (C) in clause (ii)—
                                                                13                                          (i) by striking ‘‘diagnose’’ and insert-
                                                                14                                  ing ‘‘to diagnose’’; and
                                                                15                                          (ii) by striking the period at the end
                                                                16                                  and inserting ‘‘; or’’; and
                                                                17                                  (D) by adding at the end the following:
                                                                18                                          ‘‘(iii) is a product or technology in-
                                                                19                                  tended to enhance the use or effect of a
                                                                20                                  drug, biological product, or device de-
                                                                21                                  scribed in clause (i) or (ii).’’.
                                                                22                         (2) QUALIFIED                    PANDEMIC OR EPIDEMIC PROD-
                                                                23                UCT.—Section                  319F–3(i)(7)(A) of the Public Health
tkelley on DSK3SPTVN1PROD with                                  24                Service Act (42 U.S.C. 247d–6d(i)(7)(A)) is amend-
                                                                25                ed—


                                                                             HR 307 RFS

                                                                                                                       94
                                                                  1                                 (A) in clause (i)(II), by striking ‘‘; or’’ and
                                                                  2                        inserting ‘‘;’’;
                                                                  3                                 (B) in clause (ii), by striking ‘‘; and’’ and
                                                                  4                        inserting ‘‘; or’’; and
                                                                  5                                 (C) by adding at the end the following:
                                                                  6                                         ‘‘(iii) a product or technology intended
                                                                  7                                 to enhance the use or effect of a drug, bio-
                                                                  8                                 logical product, or device described in
                                                                  9                                 clause (i) or (ii); and’’.
                                                                10                         (3) TECHNICAL                   AMENDMENTS.—Section                    319F–
                                                                11                3(i) of the Public Health Service Act (42 U.S.C.
                                                                12                247d–6d(i)) is amended—
                                                                13                                  (A) in paragraph (1)(C), by inserting ‘‘,
                                                                14                         564A, or 564B’’ after ‘‘564’’; and
                                                                15                                  (B) in paragraph (7)(B)(iii), by inserting
                                                                16                         ‘‘, 564A, or 564B’’ after ‘‘564’’.
                                                                17      SEC. 403. STRATEGIC NATIONAL STOCKPILE.
                                                                18                Section 319F–2 of the Public Health Service Act (42
                                                                19 U.S.C. 247d–6b) is amended—
                                                                20                         (1) in subsection (a)—
                                                                21                                  (A) in paragraph (1)—
                                                                22                                          (i) by inserting ‘‘consistent with sec-
                                                                23                                  tion 2811’’ before ‘‘by the Secretary to be
tkelley on DSK3SPTVN1PROD with                                  24                                  appropriate’’; and
                                                                             HR 307 RFS

                                                                                                                       95
                                                                  1                                         (ii) by inserting before the period at
                                                                  2                                 the end of the second sentence the fol-
                                                                  3                                 lowing: ‘‘and shall submit such review an-
                                                                  4                                 nually to the appropriate congressional
                                                                  5                                 committees of jurisdiction to the extent
                                                                  6                                 that disclosure of such information does
                                                                  7                                 not compromise national security’’; and
                                                                  8                                 (B) in paragraph (2)(D), by inserting be-
                                                                  9                        fore the semicolon at the end the following:
                                                                10                         ‘‘and that the potential depletion of counter-
                                                                11                         measures currently in the stockpile is identified
                                                                12                         and appropriately addressed, including through
                                                                13                         necessary replenishment’’; and
                                                                14                         (2)        in        subsection               (f)(1),           by     striking
                                                                15                ‘‘$640,000,000 for fiscal year 2002, and such sums
                                                                16                as may be necessary for each of fiscal years 2003
                                                                17                through 2006. Such authorization is in addition to
                                                                18                amounts in the special reserve fund referred to in
                                                                19                subsection (c)(10)(A).’’ and inserting ‘‘$533,800,000
                                                                20                for each of fiscal years 2013 through 2017. Such
                                                                21                authorization is in addition to amounts in the special
                                                                22                reserve fund referred to in subsection (h).’’.
                                                                23      SEC. 404. NATIONAL BIODEFENSE SCIENCE BOARD.
tkelley on DSK3SPTVN1PROD with                                  24                Section 319M(a) of the Public Health Service Act (42
                                                                25 U.S.C. 247d–f(a)) is amended—


                                                                             HR 307 RFS

                                                                                                                       96
                                                                  1                        (1) in paragraph (2)—
                                                                  2                                 (A) in subparagraph (D)—
                                                                  3                                         (i) in clause (i), by striking ‘‘and’’ at
                                                                  4                                 the end;
                                                                  5                                         (ii) in clause (ii), by striking the pe-
                                                                  6                                 riod and inserting a semicolon; and
                                                                  7                                         (iii) by adding at the end the fol-
                                                                  8                                 lowing:
                                                                  9                                         ‘‘(iii) one such member shall be an in-
                                                                10                                  dividual with pediatric subject matter ex-
                                                                11                                  pertise; and
                                                                12                                          ‘‘(iv) one such member shall be a
                                                                13                                  State, tribal, territorial, or local public
                                                                14                                  health official.’’; and
                                                                15                                  (B) by adding at the end the following
                                                                16                         flush sentence:
                                                                17                ‘‘Nothing in this paragraph shall preclude a member
                                                                18                of the Board from satisfying two or more of the re-
                                                                19                quirements described in subparagraph (D).’’; and
                                                                20                         (2) in paragraph (5)—
                                                                21                                  (A) in subparagraph (B), by striking
                                                                22                         ‘‘and’’ at the end;
                                                                23                                  (B) in subparagraph (C), by striking the
tkelley on DSK3SPTVN1PROD with                                  24                         period and inserting ‘‘; and’’; and
                                                                25                                  (C) by adding at the end the following:


                                                                             HR 307 RFS

                                                                                                                       97
                                                                  1                                 ‘‘(D) provide any recommendation, finding,
                                                                  2                        or report provided to the Secretary under this
                                                                  3                        paragraph to the appropriate committees of
                                                                  4                        Congress.’’.
                                                                            Passed the House of Representatives January 22,
                                                                        2013.
                                                                                  Attest:                                         KAREN L. HAAS,
tkelley on DSK3SPTVN1PROD with                                                                                                                 Clerk.
                                                                             HR 307 RFS

